Pathology In Depth

Library › Molecular pathology and cytogenetics: amplification and sequencing methods, cytogenetics, variant classification, inherited disease, molecular oncology, pharmacogenomics and identity testing

Molecular pathology and cytogenetics: amplification and sequencing methods, cytogenetics, variant classification, inherited disease, molecular oncology, pharmacogenomics and identity testing

Last reviewed 2026-11-17 by a board-certified pathologist. 242 references.

Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA

Scope. Molecular assays begin with specimen handling and nucleic acid extraction. Methods that do not use massively parallel sequencing include the polymerase chain reaction (PCR) and its quantitative and digital forms, isothermal amplification, hybridization-based methods, Sanger sequencing and pyrosequencing, capillary fragment analysis, methylation analysis and multiplex ligation-dependent probe amplification (MLPA).

Related page: Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation (NGS chemistry, assay validation, HGVS nomenclature and regulation) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (FISH, chromosomal microarray and optical genome mapping) Related page: Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome (fragile X Southern blot and triplet-primed PCR, SMA and DMD copy-number testing, imprinting methylation tests) Related page: Molecular Testing in Hematolymphoid Neoplasms: NGS Panels, FLT3 and BCR::ABL1 Assays, IG and TR Clonality and Molecular Measurable Residual Disease (FLT3 fragment analysis, IG and TR clonality, BCR::ABL1 quantitation and molecular MRD) Related page: Pharmacogenomic Genotyping, Identity and Parentage Testing with Short Tandem Repeats, Engraftment Monitoring and Molecular Infectious Disease Testing (STR identity and chimerism testing, viral load assays) Related page: Molecular Testing and Predictive Biomarkers on Cytology Specimens (cytology specimens, cell blocks, smears and supernatant DNA for molecular testing) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (verification statistics, detection capability and proficiency testing)

Gene structure and variant types relevant to molecular assays

Specimens, extraction and nucleic acid quality

Specimen effects on nucleic acids.

Specimen or process Effect on DNA or RNA Laboratory consequence Source
Heparinized blood Heparin inhibits PCR; heparinase treatment reverses the inhibition Heparin is removed, for example with heparinase, before PCR Poli 1993; Taylor 1997
Formalin fixation Crosslinks, fragmentation and deamination of cytosine; about one modification per 500 bases Low yield and sequence artifacts Arreaza 2016
Under-fixation Nucleic acid degradation in deeper tissue not penetrated by formalin Altered gene expression and degraded template Arreaza 2016
Over-fixation More extensive crosslinking Usable nucleic acid is harder to extract Arreaza 2016
Cytosine deamination in FFPE DNA Uracil formation causes C:G>T:A artifacts About 92% of FFPE-unique variants in one study had allele frequencies below 5% with a C>T or G>A signature; uracil-DNA glycosylase pretreatment reduces these artifacts Cazzato 2021
Hydrochloric acid decalcification Damages DNA, RNA and protein Poor PCR and in situ hybridization results Choi 2015
EDTA decalcification Longest decalcification time; best DNA yield and integrity among the methods compared Preferred for marrow biopsies needing molecular testing Choi 2015
Strong acids (hydrochloric, nitric) and RNA Increase RNA degradation Avoided when RNA testing is planned Sura 2026
Cold ischemia RNA fragmentation and altered expression; RNA integrity number (RIN) declines as ischemia lengthens Wet ice delays degradation; ischemia time is recorded Sura 2026

Quantity and quality metrics.

  • Spectrophotometry and fluorometry. For FFPE DNA, NanoDrop spectrophotometer readings were generally 2 to 10 times higher than Qubit fluorometer readings because residual RNA, single-stranded DNA and other contaminants absorb at the same wavelength. Results from different quantification methods are not comparable, and Qubit gave the most consistent results across laboratories (Arreaza 2016).
  • Amplifiability. DNA quality is also reported as the percentage of amplifiable DNA, a cycle threshold (Ct) or a ΔCt from a qPCR assay. These formats cannot be compared without a common reference (Arreaza 2016).
  • Purity ratios. An A260/A280 ratio of about 1.8 is accepted as pure DNA. A ratio of 1.6 or less indicates protein, phenol or other contaminants absorbing near 280 nm, and RNA contamination raises the ratio. Pure DNA has an A260/A230 ratio of 2.0 to 2.2; lower values indicate guanidine, EDTA, carbohydrate, salt or phenol carryover (Lucena-Aguilar 2016). For RNA, ideal A260/A280 and A260/A230 values are close to 2.0 (Sura 2026).
  • RNA integrity number. RIN runs from 1 (totally degraded) to 10 (fully intact) and is computed from the whole electropherogram. The older 28S:18S ratio of 2.0 correlates weakly with integrity (Schroeder 2006). In studies of cytology preparations and FFPE tissue, DV200 was the better indicator of sequencing performance (Sura 2026).
  • DNA integrity number. The DNA integrity number (DIN), measured on the TapeStation, indicates DNA fragmentation. In one FFPE comprehensive genomic profiling series, libraries could not be built below DIN 2.1 (Yanagita 2023).
  • Fixation for molecular testing. Japanese Society of Pathology guidance specifies 10% neutral buffered formalin and 6 to 48 hours of fixation; deamination rises with fixation beyond 72 hours, and EDTA decalcification is preferred to acid decalcification (Hatanaka 2021).
  • Tumor content. The limit of detection, particularly for gene losses, depends on the fraction of tumor cells. Microscopic review marks areas for macrodissection or microdissection to enrich tumor fraction (Jennings 2017). Laboratories set a minimum tumor content matched to assay sensitivity, and samples below it are unacceptable for testing (Jennings 2017).
  • Plasma for circulating tumor DNA. Collection tubes and processing times are taught in Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation.
  • Cytology material. Cell blocks, smears and supernatants as molecular specimens are taught in Molecular Testing and Predictive Biomarkers on Cytology Specimens.

Polymerase chain reaction principles

  • Cycle. Each PCR cycle has three steps: heat denaturation of double-stranded DNA, annealing of two primers to sequences flanking the target, and extension of the primers by a thermostable DNA polymerase (Quan 2018).
  • Exponential phase and plateau. Under ideal conditions the product doubles with each cycle, so N cycles from N0 double-stranded templates give N0 × 2^N copies (Svec 2015). Amplification stops after 30 to 40 cycles because of reagent limitation, pyrophosphate accumulation, inhibitors and self-annealing of products (Amare Amdiyee 2026). Quantitative information therefore comes from the exponential phase (Quan 2018).
  • RNA templates. RNA is first reverse transcribed. A single-stranded cDNA template is copied into its complement in the first cycle, and doubling begins in the second cycle (Svec 2015).
  • Multiplexing. Several targets are amplified in one tube when primer sets are combined, as in MLPA and the BIOMED-2 clonality assays (Schouten 2002; Langerak 2012).
  • Inhibitors. Inhibitors in the sample matrix lower amplification efficiency (Svec 2015).
  • Amplifiable template length. In the BIOMED-2 control gene PCR, amplification of 300-nucleotide fragments predicts reliable IG and TR clonality results in DNA of uncertain quality (Langerak 2012).

PCR variants and real-time detection chemistry

  • Hot-start PCR. Polymerase activity is blocked during reaction assembly, so amplification starts only after the first heating step. This reduces mispriming and primer dimers, and most real-time PCR is run hot-start (Kaltenboeck 2005).
  • Allele-specific PCR (ARMS). A primer with a mismatched 3′ terminal base does not extend, so allele-specific primers distinguish heterozygotes from either homozygote without restriction digestion or sequencing (Newton 1989).
  • Multiplex PCR for exon deletions. Simultaneous amplification of several widely separated exons detects most DMD deletions in a hemizygous male (Chamberlain 1988).
  • Nested PCR. The target is amplified first with outer primers, and that product is the template for a second amplification with inner primers. Sensitivity increases, but transfer of the first-round product raises the risk of carryover contamination; one-tube formats hold both primer pairs in a closed tube (Sun 2017).
  • Long-range PCR. A proofreading (3′→5′ exonuclease) polymerase and a modified buffer amplify 10 to 40 kb targets, up to 22 kb from human genomic DNA (Cheng 1994).
  • Relative quantification (2^−ΔΔCt). ΔCt = Ct(target gene) − Ct(reference gene); ΔΔCt = ΔCt(test sample) − ΔCt(calibrator sample); fold change = 2^−ΔΔCt. The method assumes 100% efficiency in all samples (Rao 2013).
  • Intercalating dyes. SYBR Green binds any double-stranded DNA, including primer dimers, so specificity depends on melting-curve analysis (Quan 2018; Kaltenboeck 2005).
  • Hydrolysis probes. TaqMan (5′-nuclease) probes carry a 5′ reporter and a 3′ quencher and are cleaved by the polymerase 5′→3′ exonuclease when bound to target, giving a sequence-specific signal (Quan 2018; Kaltenboeck 2005). Probes with different labels can be combined in one multiplex reaction. Cleaved probes permit no melting curve, and short amplicons of 80–130 bp are needed (Watzinger 2006).

Contamination control in amplification laboratories

  • Carryover contamination. Trace amounts of earlier PCR products contaminate new reactions and give false-positive results. PCR products are abundant and are ideal templates for reamplification (Longo 1990).
  • Uracil-N-glycosylase (UNG) and dUTP. dUTP replaces dTTP in every PCR, so all products contain uracil. Each new, fully assembled reaction is treated with uracil DNA glycosylase before cycling. The enzyme removes uracil from uracil-containing DNA and leaves thymine-containing DNA intact. The resulting apyrimidinic sites block DNA polymerases, and the enzyme is heat-inactivated before amplification begins (Longo 1990).
  • Workflow. Separate rooms are designated for sample processing and extraction, reaction assembly, the instrument and disposal of closed PCR vessels, with a strictly forward-moving workflow (Kaltenboeck 2005).
  • Laboratory design and closed systems. Pre- and post-amplification procedures, combined with automated real-time amplification and detection in a closed system, have substantially reduced false-positive results from amplicon carryover (Aslanzadeh 2004).
  • False-positive PCR from other causes. PCR-based fusion assays can also give false-positive results when disease-associated fusion transcripts are present in healthy individuals (Wolff 2007).

Real-time quantitative PCR

  • Amplification plot. A real-time PCR curve has a baseline, an exponential phase, a linear phase in which reagents become limiting and a plateau (Quan 2018).
  • Quantification cycle. The threshold is set above background within the exponential phase. The quantification cycle (Cq, also called Ct) is the cycle at which the amplification curve crosses the threshold (Quan 2018). At 100% efficiency the product doubles each cycle (Svec 2015), so a sample with 10 times more template reaches the threshold about 3.32 cycles earlier (Quan 2018).
  • Standard curve. A 10-fold dilution series of a template of known concentration is amplified, and Cq is plotted against the logarithm of the quantity. Unknowns are interpolated from the curve (Quan 2018).
  • Slope and efficiency. Efficiency is E = 10^(−1/slope) − 1. A slope of −3.32 to −3.33 for a 10-fold dilution series corresponds to 100% efficiency, a perfect doubling each cycle (Quan 2018; Svec 2015). A properly designed assay amplifies target DNA with at least 90% efficiency in the absence of interfering substances (Svec 2015).
  • Sources of error in efficiency estimates. Inhibited or saturated samples included in the linear fit reduce the slope and give falsely high efficiency estimates (Svec 2015).
  • Melting curve analysis. Fluorescent probes distinguish sequence variants by differences in melting temperature in a closed system. Melting curve analysis had a detection limit of about 10% mutant alleles for KRAS codons 12 and 13, did not define the specific mutation, and frequently required confirmation by another method (Tsiatis 2010).

Digital PCR

  • Partitioning. The reaction is divided into many partitions, each acting as an individual PCR microreactor. Partitions containing amplified target are detected by fluorescence (Quan 2018).
  • Poisson statistics. Molecules distribute randomly among partitions according to a Poisson distribution. The proportion of positive partitions gives the target concentration without a calibration curve (Quan 2018). With p the fraction of positive partitions, the mean copies per partition is λ = −ln(1 − p) (Quan 2018).
  • Precision. Precision is poor at low occupancy, is best at a mean occupancy (λ) of 1.6 copies per partition and declines as partitions saturate. Precision improves with the number of partitions (Quan 2018).
  • Rare variants and inhibitors. Partitioning reduces template competition, which allows rare mutant sequences to be detected in a background of wild-type sequence, and may increase tolerance of inhibitors (Quan 2018).
  • Clinical uses. BCR::ABL1 quantitation and molecular measurable residual disease are taught in Molecular Testing in Hematolymphoid Neoplasms: NGS Panels, FLT3 and BCR::ABL1 Assays, IG and TR Clonality and Molecular Measurable Residual Disease.

Isothermal nucleic acid amplification

Isothermal methods amplify nucleic acids at a constant temperature without a thermal cycler (Amare Amdiyee 2026).

Isothermal amplification methods.

Method Enzymes and primers Temperature Notes Source
Loop-mediated isothermal amplification (LAMP) Bst polymerase with strand-displacement activity; six primers recognizing eight regions of the target 60–65 °C Real-time turbidity or fluorescence detection Amare Amdiyee 2026
Nucleic acid sequence-based amplification (NASBA) T7 DNA-dependent RNA polymerase, RNase H and avian myeloblastosis virus reverse transcriptase; two primers, one carrying a T7 promoter 41 °C Suited to RNA viruses; DNA targets require two denaturation steps Amare Amdiyee 2026
Helicase-dependent amplification (HDA) Helicase unwinds DNA in place of heat; single-stranded binding protein; DNA polymerase 37 °C (original); 60–65 °C (thermophilic tHDA with Tte-UvrD and Bst polymerase) Mimics in vivo replication Amare Amdiyee 2026
Transcription-mediated amplification (TMA) Target capture with magnetic beads, then isothermal amplification of RNA such as 23S rRNA Constant temperature Automated real-time detection; detects rRNA from serum and swabs Getman 2021

Strand displacement amplification, recombinase polymerase amplification (RPA) and rolling circle amplification are other isothermal methods; SDA products are detected by molecular beacons or lateral flow (Amare Amdiyee 2026).

Point-of-care NAATs and molecular infectious disease assays are taught in Pharmacogenomic Genotyping, Identity and Parentage Testing with Short Tandem Repeats, Engraftment Monitoring and Molecular Infectious Disease Testing and Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.

Hybridization-based methods

Sanger sequencing and pyrosequencing

  • Method. PCR products are purified, cycle sequenced with fluorescent dye-terminator reagents and separated by capillary electrophoresis. The electropherogram is read electronically against a threshold and by visual inspection (Tsiatis 2010).
  • Scope. Sanger sequencing detects essentially all base substitutions and small insertions and deletions in the amplified region (Tsiatis 2010).
  • Detection limit. In a dilution study of KRAS codon 12 and 13 mutations, the limit of detection was about 15% to 20% mutant alleles for Sanger sequencing, 5% for pyrosequencing and 10% for melting curve analysis (Tsiatis 2010). The Sanger limit varies with the sequence, the laboratory and the specific mutation, partly because of differences in fluorophore intensity. Sanger sequencing was less sensitive for mutations at the first position of codon 12 (Tsiatis 2010).
  • Electronic calling thresholds. With an electronic cutoff of 10%, Sanger sequencing gave 11.1% false-positive and 6.1% false-negative results in the same study (Tsiatis 2010).
  • Pyrosequencing. Pyrophosphate released at each nucleotide incorporation is converted to light through an enzymatic cascade. Pyrosequencing occasionally requires confirmation by another method (Tsiatis 2010). It also showed that two KRAS mutations in one specimen were on the same allele (in cis) (Tsiatis 2010).
  • Tumor fraction and allele fraction. In two specimens with 75% to 80% tumor cells on histologic review, pyrosequencing measured mutant allele fractions of 8% to 49% (Tsiatis 2010). Expected allele fraction in relation to tumor cellularity and NGS detection limits is taught in Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation.

Capillary fragment analysis

DNA methylation analysis

Multiplex ligation-dependent probe amplification

  • Principle. Each MLPA probe consists of two oligonucleotides that hybridize next to each other on the target. Only hybridized, adjacent probe halves are ligated, and only ligated probes are amplified. All ligated probes share identical end sequences, so a single primer pair amplifies up to 40 probes, each yielding a product of unique size (Schouten 2002). The method requires 20 ng of human DNA (Schouten 2002).
  • Single-nucleotide discrimination. The ligation step distinguishes single-nucleotide differences at the probe junction (Schouten 2002).
  • Applications in the original description. Exon deletions and duplications in BRCA1, MSH2 and MLH1, trisomies including Down syndrome, chromosomal aberrations in cell lines and tumors, and SNP and mutation detection (Schouten 2002).
  • Copy-number applications. Two MLPA reactions cover all 79 DMD exons and detect deletions and duplications in affected males and female carriers, which multiplex PCR does not detect. MLPA measures SMN1 and SMN2 copy number and detects carriers, which PCR-RFLP misses (Stuppia 2012). Disease testing strategies for DMD and SMA are taught in Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome.

Comparison of non-NGS molecular methods

Method Analyte or output Detection limit, input or performance Limitations Source
Sanger sequencing Sequence of an amplicon About 15%–20% mutant alleles Variants below the detection limit; copy-number changes; variants outside the amplicon Tsiatis 2010
Pyrosequencing Short sequence and allele quantity About 5% mutant alleles Variants outside the short read; occasionally needs confirmation Tsiatis 2010
Melting curve analysis Melting temperature shift About 10% mutant alleles Does not name the specific mutation Tsiatis 2010
Real-time qPCR Relative or standard-curve quantity Efficiency of at least 90% in a properly designed assay Quantity depends on a calibrator; inhibitors distort efficiency Svec 2015; Quan 2018
Digital PCR Absolute copies by Poisson counting Precision best at λ of 1.6 copies per partition High target loads saturate partitions Quan 2018
Methylation-specific PCR Methylated versus unmethylated alleles 0.1% methylated alleles Sites outside the primer sequence Herman 1996
MLPA Relative copy number of up to 40 sequences 20 ng DNA Point mutations outside probe sites; balanced rearrangements Schouten 2002; Stuppia 2012
MS-MLPA Methylation and copy number together Methylation-sensitive HhaI sites within probes CpG sites without an HhaI site in a probe Nygren 2005
Capillary fragment analysis Amplicon size Size ranges defined for each multiplex reaction Sequence changes that do not alter length Langerak 2012

Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation

Scope. Next-generation sequencing (NGS) sequences millions of DNA or cDNA fragments in parallel and detects single-nucleotide variants (SNVs), insertions and deletions (indels), copy-number alterations (CNAs) and structural variants (SVs) in one assay.

Related page: Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA (specimens, extraction, FFPE artifacts, PCR, Sanger and MLPA) Related page: Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening (germline and somatic variant classification, exome and genome sequencing, secondary findings and GINA) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (FISH, microarray and optical genome mapping for structural variants) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (tumor mutational burden, MSI by NGS, germline findings on tumor sequencing and organ biomarker links) Related page: Molecular Testing in Hematolymphoid Neoplasms: NGS Panels, FLT3 and BCR::ABL1 Assays, IG and TR Clonality and Molecular Measurable Residual Disease (myeloid and lymphoid NGS panels and NGS-based MRD) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (clonal hematopoiesis and its VAF thresholds) Related page: Molecular Testing and Predictive Biomarkers on Cytology Specimens (cytology specimens and supernatant cell-free DNA for NGS) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (CLIA verification statistics, detection capability and proficiency testing)

Library preparation and sequencing chemistry

  • Library construction. For hybridization capture, DNA is sheared to fragments of uniform size, then end repaired, A-tailed and ligated to sequencing adaptors, followed by PCR amplification and clean-up. Fragment size is checked by gel electrophoresis or a Bioanalyzer (Jennings 2017).
  • Indexes. Target sequences are tagged with sample-specific indexes and sequencing adaptors that anchor them to oligonucleotides on the sequencing substrate (Jennings 2017).
  • Sequencing platforms. Clinical platforms use sequencing by synthesis (Illumina) or ion semiconductor sequencing (Ion systems) (Jennings 2017).
  • Run metrics. Typical run acceptance values are clusters passing filter above 80% and an alignment rate above 95%. Cluster density and alignment rate are monitored in every run, and GC bias is determined during validation and monitored with every run (Jennings 2017).
  • Read length. Short reads are 150–300 bp, and long-read platforms average more than 10 kb per read (Mantere 2019).

Target enrichment by amplicon and hybrid capture

Comparison of amplicon-based and hybrid capture-based enrichment.

Feature Amplicon-based enrichment Hybrid capture-based enrichment Source
Principle Target-specific primers amplify each region Long biotinylated oligonucleotide probes capture sheared fragments Jennings 2017
Hands-on time Typically shorter Longer Jennings 2017
Allele dropout Occurs when a SNP or indel in the primer region prevents primer binding; lowers coverage and distorts VAF Circumvented Jennings 2017
Indels Missed if the indel removes the primer site or changes amplicon size substantially Detected Jennings 2017
Read quality at fragment ends Diminishes at amplicon ends; tiled overlapping amplicons compensate Not limited to fixed ends Jennings 2017
Library complexity and duplicates Difficult to measure because all amplicons share identical 5′ and 3′ ends Reads have unique start and stop coordinates, so PCR duplicates are identified and removed Jennings 2017
Off-target sequence Limited to primer design Neighboring regions are captured, which reduces on-target coverage if unbalanced; repetitive sequences deplete probes Jennings 2017
Copy-number analysis Algorithms exist; accuracy depends on the number of amplicons across the gene Algorithms exist; accuracy depends on the number of probes across the gene Jennings 2017
Fusion detection in DNA Not practical because most breakpoints are intronic Probes tile introns of the genes most often involved Jennings 2017
Sensitivity to base composition Primer-dependent Sensitive to sample base composition Jennings 2017

Copy-number estimates from a single hotspot region are less accurate than estimates averaged across probes or amplicons covering all exons (Jennings 2017). Exome and genome sequencing for constitutional disease are taught in Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening.

Molecular barcodes and error suppression

Bioinformatics pipeline and sequencing quality metrics

  • Pipeline steps. The NGS data analysis pipeline has four primary operations: base calling, read alignment, variant identification and variant annotation (Jennings 2017). Indel-containing reads need alignment algorithms designed for that task (Jennings 2017).
  • Variant call format. Variant calls are represented in standardized formats, of which the variant call format (VCF) was the most widely used in clinical laboratories. Required VCF fields are genomic coordinates, reference nucleotides and variant nucleotides. Complex, multinucleotide and large structural variants are difficult to represent in VCF version 4.2 (Li 2017).
  • Left and right alignment. HGVS describes variants right-aligned (3′ shifted), and VCF specifications require left-aligned representation, so the same indel in a repeat can have different coordinates in the two formats (Li 2017).
  • Pipeline validation. The AMP recommendations for bioinformatics pipelines, developed with CAP and the American Medical Informatics Association, comprise 17 best-practice recommendations on pipeline design, development, validation and operation, with emphasis on a trained and qualified molecular professional (Roy 2018). Reference materials appropriate to the variant types and their ranges are used to validate the pipeline (Jennings 2017).
  • Depth of coverage. Depth is the number of aligned reads containing a given nucleotide position (Jennings 2017).
  • Base quality. A Phred quality score of Q20 corresponds to an error rate of 1%; with that error rate, the probability of five or more errors at one base is 10.78% (Jennings 2017).
  • Copy-number and loss of heterozygosity. Read counts in a region, normalized to the average depth across the sample, reflect relative DNA content. Allele frequencies at common SNVs indicate CNAs or loss of heterozygosity (Jennings 2017).
  • Strand bias and systematic error. Read quality, read length, strand bias and read depth are quality metrics. Systematic errors arise in repetitive sequence and pseudogenes (Jennings 2017).
  • Transition/transversion ratio. The transition/transversion ratio is a quality metric for exome and genome sequencing (Jennings 2017).
  • Phred scale. Q = −10 log10 P, where P is the probability of an incorrect base call. Q30 is 1 error in 1,000 calls (99.9% accuracy) and is the usual NGS quality benchmark (Illumina technical note).

Minimum depth of coverage.

Setting Depth Basis Source
Germline testing Minimum of 30× with balanced forward and reverse reads, usually sufficient Germline variants are heterozygous or homozygous Jennings 2017
Somatic panels More than 250 reads per tested amplicon or target With 5% mutant allele frequency and 250 reads, the probability of four or fewer mutant reads is 0.457%; a call threshold of five reads gives a false-negative probability below 0.5% Jennings 2017
Tissue with low tumor cellularity Average of at least 1000× may be required Tissue heterogeneity, subclones and stromal admixture Jennings 2017
Mitochondrial DNA Average of at least 5000× Detection of heteroplasmic variants Jennings 2017
  • Limit of detection and intended use. For somatic panels guiding targeted therapy, the lower VAF limit with clear clinical utility is generally about 5%. Measurable residual disease testing may need detection well below 1% (Jennings 2017).
  • Expected VAF and tumor content. For a diploid tumor, the expected VAF of a heterozygous variant equals tumor cellularity × the fraction of tumor cells carrying the variant × 0.5. An assay with a validated lower limit of 10% VAF misses a heterozygous variant present in 50% of tumor cells when tumor cellularity is below 40% (Jennings 2017).

Long-read sequencing

  • Platforms. Single-molecule real-time (SMRT) sequencing (Pacific Biosciences) and nanopore sequencing (Oxford Nanopore Technologies) sequence single DNA molecules with average reads longer than 10 kb (Mantere 2019).
  • Strengths. Long reads detect structural variants missed by short-read NGS, sequence through repeat expansions and regions of extreme GC content, resolve variant phasing and distinguish genes from their pseudogenes (Mantere 2019). Because no PCR is required, the native DNA retains base modifications such as methylation, which long-read platforms detect directly (Mantere 2019).
  • Repeat expansions. Long-read studies have measured expansion length, interruption motifs and somatic variability in HTT (Huntington disease), DMPK (myotonic dystrophy type 1) and C9orf72 (amyotrophic lateral sclerosis and frontotemporal dementia) (Mantere 2019).
  • Error rate. Early SMRT reads averaged about 1.5 kb with an error rate near 13%, mainly false insertions (Mantere 2019).

RNA-based fusion detection

Circulating tumor DNA and liquid biopsy

  • Preanalytic requirements. ctDNA testing is optimally performed on plasma collected in cell stabilization tubes or EDTA tubes, with EDTA tubes processed within 6 hours of collection (Merker 2018).
  • Concordance with tissue. ctDNA results are discordant with tumor genotyping in some patients, and tumor tissue genotyping confirms results reported as undetected by ctDNA tests (Merker 2018).
  • Clinical validity. In the ASCO/CAP joint review, some ctDNA assays showed clinical validity and utility in certain advanced cancers. There was no evidence of clinical utility and little evidence of clinical validity in early-stage cancer, treatment monitoring or residual disease detection, and no evidence supporting ctDNA assays for cancer screening outside a clinical trial (Merker 2018).
  • Clonal hematopoiesis. With high-intensity sequencing of cell-free DNA and matched white blood cell DNA (508 genes, more than 60,000× raw depth), most cfDNA mutations had features of clonal hematopoiesis: 81.6% in controls and 53.2% in patients with cancer (Razavi 2019). Matched white blood cell sequencing distinguishes clonal hematopoiesis variants from tumor-derived variants (Razavi 2019). Clonal hematopoiesis definitions and VAF thresholds are taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.
  • Fragment size and clearance. Cell-free DNA fragments range from about 40 to 200 bp with a peak at about 166 bp (Kustanovich 2019). After complete resection, the half-life of ctDNA was estimated at 114 minutes (Diehl 2008).
  • Cytology supernatants. Cell-free DNA from cytology supernatants is taught in Molecular Testing and Predictive Biomarkers on Cytology Specimens.

Analytical validation of NGS assays

CLIA verification of unmodified FDA-cleared or approved tests and establishment of performance specifications for modified tests and laboratory-developed tests (42 CFR 493.1253) are taught in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry.

AMP/CAP NGS oncology panel validation recommendations (Jennings 2017).

  • Optimization and familiarization. A phase of optimization and familiarization precedes formal validation. It addresses library complexity, required depth, preliminary performance with reference materials, mixing studies for each variant type and the bioinformatics pipeline. Data from this phase are not part of the validation (Jennings 2017).
  • Error-based approach. The laboratory director identifies potential sources of error throughout the analytical process and addresses each through test design, validation or quality control, following CLSI EP23 (Jennings 2017).
  • Positive percentage agreement and positive predictive value. PPA and PPV are established and documented for each reported variant class (SNVs, indels, CNAs and SVs) (Jennings 2017).
  • Reference materials. Well-characterized cell lines such as HapMap NA12878, cell-line mixtures and NIST Reference Material 8398 estimate performance and detection limits. FFPE cell blocks made from cell lines are a renewable reference material (Jennings 2017).
  • Number of samples. A minimum of 59 samples is recommended to establish quality metrics and performance characteristics. Solving n = ln(α) ÷ ln(r) for 95% confidence (α = 0.05) and 95% reliability (r = 0.95) gives 59. After 59 representative samples, the highest observed false-positive rate defines the rate that 95% of samples will not exceed with 95% confidence (Jennings 2017).
  • Lower limit of detection. The lower limit of detection (LLOD) is the minor allele fraction detected reliably in 95% of samples. It is determined for each variant type with a minimum of 59 samples. Twenty samples with 19 or 20 correct results do not give 95% confidence of at least 95% reliability (Jennings 2017).
  • Rule of three. To claim with 95% confidence that fewer than 1% of cells carry a translocation by FISH, 300 cells must be counted without a positive. Counting 100 cells supports no such claim (Jennings 2017).
  • Precision. A minimum of three samples is tested across all steps, instruments, personnel and reagent lots over an extended period (Jennings 2017).
  • Validation sample set. Validation samples include previously characterized clinical samples of each intended specimen type and each intended variant type, samples with the most common relevant mutations, two or more consensus-sequence reference samples covering all regions of the panel, and a minimum of 59 samples overall (Jennings 2017).
  • Tolerance intervals. A 95% lower confidence limit describes the average depth across samples. A 95% tolerance interval describes the minimum depth above which 95% of individual samples fall. With a mean depth of 275 reads and an SD of 50 reads across 100 samples, the lower confidence limit of the mean was above 266 reads while the 95% lower tolerance limit for any single sample was 179 reads (Jennings 2017).
  • Tumor content and specimen acceptance. Minimum tumor content and macrodissection are taught in Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA.
  • Sensitivity controls. Runs include sensitivity controls at the LLOD where validation data do not establish more than 95% reliability and confidence. Linearized plasmid controls perform similarly to formalin-fixed cell-line DNA when fragmented to comparable size (Jennings 2017).
  • Changes after validation. Added loci, new reagent versions, new pipeline versions or a new instrument model require documented evidence that potential errors are unlikely or readily detected. A platform change may require complete validation (Jennings 2017).
  • Proficiency testing. Participation in proficiency testing is required for CLIA certification and accreditation. When no external quality assessment survey exists for an analyte, laboratories conduct alternative external quality assessment (Jennings 2017).

Statistics for verification studies, detection capability and proficiency testing are taught in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry.

HGVS sequence variant nomenclature

HGVS reference sequence prefixes and variant syntax.

Element Rule Example Source
g. Genomic reference sequence NC_000023.11:g.32389644G>A HGVS Nomenclature
c. Coding DNA reference sequence; c.1 is the A of the ATG start codon; numbering ends at the last nucleotide of the stop codon NM_004006.3:c.4375C>T HGVS Nomenclature
n. Non-coding RNA reference sequence NR_002196.1:n.601G>T HGVS Nomenclature
r. RNA level NM_002354.2:r.−358_555::NM_000251.2:r.212_*279 (adjoined transcript) HGVS Nomenclature; Hart 2024
p. Protein level; a predicted consequence is written in parentheses p.(Arg1459Ter) HGVS Nomenclature
m. Mitochondrial reference sequence NC_012920.1:m.3243A>G HGVS Nomenclature
5′ and 3′ untranslated regions Minus sign before c.1; asterisk after the stop codon c.-26; c.*85 HGVS Nomenclature
Intronic positions Offset from the nearest exon nucleotide c.530+6; c.531-23 HGVS Nomenclature
Substitution > c.4375C>T HGVS Nomenclature
Deletion del c.4375_4379del HGVS Nomenclature
Duplication dup c.4375_4385dup HGVS Nomenclature
Insertion ins c.4375_4376insACCT HGVS Nomenclature
Deletion-insertion delins c.4375_4376delinsAGTT HGVS Nomenclature
Frameshift First changed amino acid, new residue, fs, then Ter and the position of the new stop; short form omits the new residue and stop p.Arg97ProfsTer23; p.Arg97fs HGVS Nomenclature
Reference sequence version Required; an unversioned accession is ambiguous NC_000023.11 HGVS Nomenclature
  • Historical names. Current nomenclature is used, with the historical name given in addition where one exists. Reference sequences come from RefSeq with version number or from the Locus Reference Genomic database (Richards 2015).
  • Coding position to codon. Dividing a c. position by three and rounding up gives the codon number, so c.4375 is in codon 1459 (HGVS Nomenclature).

HGVS version in force and previous version.

Item HGVS Nomenclature 21.1 series (21.1.5 current on 2026-11-17; Hart 2024) HGVS recommendations v15.11 (previous; den Dunnen 2016)
Governance HGVS Variant Nomenclature Committee under HUGO; open change proposals on GitHub Sequence Variant Description Working Group under HGVS, the Human Variome Project and HUGO; community consultation step
Syntax definition Formal computational grammar in Extended Backus-Naur Form Focus on removing inconsistencies and tightening definitions for automatic processing
Versioning Semantic versioning X.Y.Z; major version changes only for backward-incompatible changes Version numbers assigned to allow users to state the version used
  • Additions in the 21.1 series. MANE Select transcripts are recommended where appropriate. Gene fusion transcripts are written as adjoined transcripts with a double colon, aligned with VICC fusion nomenclature, and the terms "RNA fusion" and "fusion transcript" are deprecated (Hart 2024).

Companion and complementary diagnostics

Regulation of molecular laboratories

Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics

Scope. Cytogenetics studies chromosomes by karyotype and fluorescence in situ hybridization (FISH). Cytogenomics adds genome-wide copy-number and structural methods: chromosomal microarray (CMA) and optical genome mapping (OGM).

Related page: Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA (MLPA, Southern blot and methylation methods) Related page: Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation (NGS fusion detection, validation and the FISH rule of three) Related page: Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening (inheritance, risk calculation and sequence variant classification) Related page: Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome (Prader–Willi and Angelman methylation testing, uniparental disomy mechanisms, fragile X) Related page: Reproductive Endocrinology and Pregnancy Screening: Gonadal Hormones, hCG and Prenatal Testing (cell-free DNA prenatal screening and serum screening) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (cytogenetic workup of myeloid neoplasms and complex karyotype) Related page: Flow Cytometry, FISH, Microbiology and Electron Microscopy on Cytology Specimens (FISH on cytology material) Related page: Ancillary Tests, Indications and Management in Urine Cytology (UroVysion FISH) Related page: Biliary adenocarcinoma on brushing and ancillary testing (biliary brushing FISH)

Conventional karyotype

  • Specimens. Chromosomes are prepared from dividing cells of blood lymphocytes, skin fibroblasts, amniocytes, placenta, bone marrow and tumor specimens (Howe 2014).
  • Blood cultures. Phytohemagglutinin (PHA) is a mitogen for T cells; 72 h after PHA is added, about 45% of cells are in S phase. Pokeweed mitogen is used when B cells are analyzed (Howe 2014).
  • Bone marrow cultures. Marrow cells divide actively and need no mitogen. Marrow for cytogenetics is collected in sodium heparin (Howe 2014). Heparin removal before PCR-based testing is described in Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA.
  • Metaphase arrest and harvest. Colcemid disrupts spindle fibers and holds cells in metaphase, when chromosomes are most condensed. Cells are swollen in hypotonic solution and fixed in Carnoy fixative (3:1 methanol and glacial acetic acid) (Howe 2014).
  • G-banding. Trypsin digestion followed by Giemsa staining (GTG) produces light and dark bands. Heterochromatin with little transcriptional activity keeps more of its histones protected from trypsin and stains darkly; transcriptionally active regions stain lightly (Howe 2014).
  • Resolution. CMA detects imbalances at higher resolution than a G-banded karyotype, whose resolution is about 5 Mb (Miller 2010).
  • Band level. ISCN defines five banding levels. European guidelines set minimum G-band quality at fewer than 300 bands per haploid set (bphs) to confirm aneuploidy, 300 bphs to exclude large known rearrangements, 400 bphs for small expected rearrangements and routine prenatal preparations, and 550 bphs for routine postnatal preparations and abnormal prenatal ultrasound without array (Silva 2019).
  • Cells examined in constitutional studies. Routine postnatal studies fully analyze at least 2 cells, and routine prenatal studies 2 cells from 2 cultures. To exclude mosaicism, 2 analyzed cells plus 28 additional counted cells (30 in total) are examined. Karyotype resolution is 5–10 Mb and misses mosaicism below 10% (Silva 2019).
  • Cells examined in neoplastic studies. A normal diagnostic karyotype requires at least 20 metaphases, which excludes an abnormal clone of 14% with 95% confidence. When a clone is known, 10 metaphases may suffice at follow-up. A clone is the same structural abnormality or chromosome gain in at least 2 metaphases, or the same chromosome loss in at least 3 (Rack 2019).
  • Interphase FISH counts in constitutional studies. At least 50 nuclei are scored for aneuploidy and at least 100 to detect mosaicism; 5 metaphases are scored for a locus-specific probe (Silva 2019).
  • Indications retained for karyotype. G-banded karyotype is reserved for patients with obvious chromosomal syndromes such as Down syndrome, a family history of chromosomal rearrangement or a history of multiple miscarriages (Miller 2010).

ISCN cytogenomic nomenclature

  • Editions. The International System for Human Cytogenomic Nomenclature (ISCN) is maintained by the International Standing Committee on Human Cytogenomic Nomenclature. It describes abnormalities detected by karyotyping, FISH, microarray, genome mapping, region-specific assays and high-throughput sequencing. The current edition, ISCN 2024, was published in September 2024 (ISCN 2024; Wang 2025); ISCN 2020 is the previous edition. The specific changes introduced by ISCN 2024 are not taught. The symbols below are the basic symbols of a laboratory summary based on ISCN 2013 (WSLH cytogenetics nomenclature), which are used unchanged in ISCN 2016-based European guidelines (Silva 2019; Rack 2019).
  • Genome mapping nomenclature. The ISCN Standing Committee published a nomenclature for genome mapping results that covers aneuploidy, balanced and unbalanced structural variants and copy-number changes (Moore 2023).
  • Order of a karyotype string. Modal chromosome number, then sex chromosomes, then abnormalities, separated by commas. Chromosomes in a rearrangement are listed in parentheses and separated by a semicolon, followed by the breakpoints in a second set of parentheses. Band numbers are counted from the centromere outward along each arm (WSLH cytogenetics nomenclature).

Karyotype symbols (ISCN 2013-based summary; WSLH cytogenetics nomenclature).

Symbol Meaning
+ and − Gain or loss of a chromosome
t Translocation
der Derivative chromosome; used when only one chromosome of a translocation is present or one chromosome has two or more structural abnormalities
del Deletion
dup Duplication of part of a chromosome
inv Inversion
i Isochromosome, with both arms identical
r Ring chromosome
mar Marker chromosome, an unidentified chromosome fragment
dic; psu dic Dicentric chromosome; pseudodicentric chromosome with only one active centromere
ins; trp; fra Insertion; triplication; fragile site
/ Separates cell lines or clones
// Separates recipient and donor cell lines after bone marrow transplantation
ish Precedes results of FISH analysis
p; q Short arm; long arm
mat; pat; dn Maternally derived; paternally derived; de novo

Karyotype notation examples.

  • 46,XX,t(1;2)(p32;q22): female with a balanced translocation between chromosomes 1 and 2, breakpoints at 1p32 and 2q22 (WSLH cytogenetics nomenclature).
  • 45,XX,der(14;21)(q10;q10): female carrier of a Robertsonian translocation between chromosomes 14 and 21 (Kolgeci 2015). rob(14;21)(q10;q10) is an accepted equivalent notation (Rack 2019).
  • 45,X/46,XX; 45,X/46,X,r(X); 46,X,i(Xq): Turner syndrome karyotypes with mosaicism, a ring X and an isochromosome Xq (Gravholt 2024).
  • t(9;22)(q34;q11.2): the translocation present in at least 90% of patients with chronic myeloid leukemia (Wolff 2007).

Structural and numerical chromosome abnormalities

Abnormality types and their laboratory significance.

Abnormality Definition or mechanism Laboratory and clinical significance Source
Aneuploidy from nondisjunction Gain or loss of a whole chromosome Main mechanism of trisomy 21 El-Gilany 2011
Robertsonian translocation End-to-end fusion of two acrocentric chromosomes at or near the centromeres, written der(14;21)(q10;q10) Balanced carriers are silent carriers with miscarriages and offspring with translocation trisomy; carriers of a rearrangement between chromosome 21 and another acrocentric chromosome (13, 14, 15 or 22) can have children with Down syndrome or balanced carrier children Kolgeci 2015
Balanced reciprocal translocation Exchange between two chromosomes without net gain or loss Not detected by microarray; detected by karyotype Miller 2010
Inversion Segment reversed within one chromosome Inversion polymorphisms between inverted homologous sequences predispose to non-allelic homologous recombination in meiosis through inversion loops, producing deletions and duplications Weise 2012
Isochromosome Two identical arms 46,X,i(Xq) and isodicentric Xp account for about 15% of Turner syndrome karyotypes Gravholt 2024
Ring chromosome Ring formed after loss of chromosome ends 45,X/46,X,r(X) is a rare Turner syndrome karyotype Gravholt 2024
Marker chromosome Unidentified chromosome fragment Characterized further by FISH or microarray WSLH cytogenetics nomenclature
Recurrent microdeletion and microduplication Non-allelic homologous recombination between flanking low-copy repeats or segmental duplications Same-size de novo rearrangements; many regions have reciprocal deletion and duplication syndromes Weise 2012
Mosaicism Two or more cell lines, separated by / in ISCN Low-level mosaicism is generally not detected by microarray Miller 2010
  • Robertsonian carrier risk. Carriers of rob(14;21) have about a 12%–15% chance of a child with Down syndrome, in addition to a miscarriage risk (Kolgeci 2015).
  • Pericentric inversions. Balanced carriers are usually unaffected, and inversion loop formation in meiosis can produce recombinant chromosomes with a duplication and a deletion in offspring (Liehr 2019).
  • Small supernumerary marker chromosomes (sSMC). sSMC are present in 0.043% of newborns, and about 30% derive from chromosome 15. Syndromic sSMC include inv dup(22q11.2) in cat-eye syndrome and i(12p) in Pallister–Killian syndrome (Cui 2016).
  • Isochromosome 12p in Pallister–Killian syndrome. Pallister–Killian syndrome is mosaic tetrasomy 12p from a supernumerary i(12p), with a prevalence of about 1 in 20,000. Tetrasomy 12p is found in 0%–2% of lymphocytes, 50%–100% of fibroblasts and chorionic villi, and 100% of amniocytes and marrow cells, so a blood karyotype misses it; buccal MLPA or microarray is recommended first (Arghir 2021).

Fluorescence in situ hybridization

  • Principle. A fluorochrome-labeled DNA probe hybridizes to its chromosomal target in situ. Metaphase FISH shows chromosome morphology and signal position directly. Interphase FISH works on nondividing cells, gives rapid results and is applied to uncultured marrow, FFPE sections, disaggregated cells, smears and touch preparations (Wolff 2007).

  • FISH versus PCR. FISH is superior to PCR for numerical abnormalities and is preferred where breakpoint heterogeneity limits DNA-based PCR. PCR-based assays are preferred for residual disease because of greater analytic sensitivity (Wolff 2007).

  • Regulatory status of probes. Few probe kits are FDA approved. Most clinical probes are analyte-specific reagents whose performance must be established by the laboratory (Wolff 2007).

  • Probe classes. Locus-specific probes target a defined region or gene: alpha-satellite repeats for centromeres and single-copy sequences for subtelomeric and gene regions. Painting probes cover a chromosomal band, an entire chromosome or the whole genome and are used mostly in research to characterize structural rearrangements in metaphase chromosomes (Cui 2016).

  • Microdeletion detection. Locus-specific probes detect submicroscopic deletions such as 22q11.2 in DiGeorge syndrome and 15q11.2 in Prader–Willi and Angelman syndromes. Interphase FISH requires no cell culture and allows rapid aneuploidy screening (Cui 2016).

FISH probe designs.

Probe design Examples Normal pattern Abnormal pattern Source
Enumeration (centromeric alpha-satellite) Chromosome 8 centromere; X/Y Two signals per chromosome pair Gain or loss of signals Wolff 2007
Dual-color dual-fusion BCR::ABL1, IGH::BCL2, PML::RARA Two red (ABL1) and two green (BCR) signals for BCR::ABL1 Two fusion signals with one red and one green signal in a balanced translocation Wolff 2007
Single-fusion extra-signal ETV6::RUNX1, BCR::ABL1 extra-signal Separate signals for each uninvolved locus One fusion, one normal signal of each color and a small extra signal from the residual locus Wolff 2007
Break-apart KMT2A, CBFB Two fused (yellow) signals One fused signal plus one separate red and one separate green signal Wolff 2007

Chromosomal microarray

  • First-tier test. CMA gives a diagnostic yield of 15% to 20% in unexplained developmental delay or intellectual disability, autism spectrum disorder and multiple congenital anomalies, compared with about 3% for a G-banded karyotype excluding recognizable syndromes such as Down syndrome. CMA replaces the karyotype as the first-tier cytogenetic test in these patients (Miller 2010).
  • Array designs. Copy-number arrays use long oligonucleotide probes (about 60-mer) with better signal-to-noise ratios. SNP arrays also genotype polymorphic sites and need more consecutive probes for a comparable call (Miller 2010).
  • SNP arrays and homozygosity. SNP arrays detect long stretches of homozygosity, which can represent uniparental disomy or unsuspected consanguinity pointing to an autosomal recessive disorder (Miller 2010).
  • Resolution requirement. A clinical array consistently detects imbalances smaller than 5 Mb, with uniform coverage across the genome (Miller 2010).
  • Limitations. Microarray detects low-level 45,X mosaicism poorly below about 10% and has difficulty interpreting some structural variants such as a mosaic isodicentric Xp (Gravholt 2024).

ACMG/ClinGen CNV classification (Riggs 2020).

Element Content Source
Sections scored (1) genomic content; (2) overlap with established haploinsufficient, triplosensitive or benign genes or regions; (3) number of protein-coding genes; (4) published literature, public databases and internal laboratory data; (5) inheritance pattern and family history of the patient Riggs 2020
Pathogenic 0.99 points or more Riggs 2020
Likely pathogenic 0.90 to 0.98 points Riggs 2020
Uncertain significance 0.89 to −0.89 points Riggs 2020
Likely benign −0.90 to −0.98 points Riggs 2020
Benign −0.99 points or fewer Riggs 2020
Example score Region without protein-coding or other known functionally important elements: −0.60 points Riggs 2020
Example score Copy-number loss observed de novo: section 5 directs the scorer to the de novo categories of section 4 Riggs 2020
Reporting threshold Only CNVs that meet the laboratory's own reporting thresholds are evaluated with the metric Riggs 2020
Nomenclature in reports ISCN for CMA results; HGVS may be preferable for NGS-detected CNVs; nomenclature does not replace a plain description of the imbalance Riggs 2020

Copy losses and copy gains have separate scoring metrics (Riggs 2020). Sequence variant classification is taught in Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening.

Optical genome mapping

  • Principle. OGM images very long linear single DNA molecules (median size greater than 250 kb) labeled at specific sequence sites. Ultra-high-molecular-weight DNA is isolated from blood, cultured cells, amniocytes or chorionic villi (Mantere 2021).
  • Analysis pipelines. A copy-number pipeline uses normalized molecule coverage to detect large unbalanced aberrations and aneuploidy. A structural variant pipeline compares labeling patterns and distances with the reference (Mantere 2021).
  • Performance. OGM reached 100% concordance with standard assays for constitutional aberrations with non-centromeric breakpoints (Mantere 2021). It detects balanced and unbalanced structural variants that karyotype resolution or microarray miss (Mantere 2021).
  • Hematologic malignancies. An international consortium published consensus guidance on validation, quality control, analysis and interpretation of OGM in hematologic malignancies, noting that OGM consolidates the information of karyotype, FISH and microarray in one assay (Levy 2024).

Constitutional autosomal and sex chromosome aneuploidies

Constitutional aneuploidies.

Condition Karyotypes and frequencies Laboratory points Source
Down syndrome (trisomy 21) Nondisjunction 96.1%, translocation 3.1%, mosaic 0.8% in 712 cytogenetically confirmed cases Translocation trisomy can be inherited from a parent who is a silent Robertsonian carrier; maternal age is the most important element of risk estimation in screening programs El-Gilany 2011; Kolgeci 2015; Morris 2009
Trisomy 18 (Edwards syndrome) Full trisomy about 94%; mosaic trisomy less than 5%; partial trisomy 18q about 2% Live-born prevalence 1/6,000–1/8,000 and overall prevalence 1/2,500–1/2,600 because of fetal loss and termination; the extra chromosome is most often maternal, and prevalence rises with maternal age; recurrence risk about 1% after full trisomy 18 Cereda 2012
Aneuploidy in stillbirth Among 32 aneuploid stillbirths: trisomy 21 (10), trisomy 18 (10), trisomy 13 (2), monosomy X (8) Detected by karyotype or CMA; CMA yields results more often in stillbirth Reddy 2012
Turner syndrome 45,X 40%–50%; 45,X/46,XX 15%–25%; 46,X,i(Xq) or idic(Xp) about 15%; 45,X/46,XY 10%–12%; 45,X/47,XXX about 3%; 45,X/46,X,r(X) rare Diagnosis requires a female phenotype, one X chromosome with complete or partial absence of the second sex chromosome, and typical features Gravholt 2024
Turner syndrome with Y material 45,X/46,XY or Y material found by karyotype or FISH Screening for Y material by PCR or another molecular method in 45,X with virilization; individualized decision on gonadectomy because of gonadoblastoma and dysgerminoma risk Gravholt 2024
Conditions excluded from Turner syndrome Deletion distal to Xq24; women older than 50 years with less than 5% 45,X cells Distal Xq deletions present as premature ovarian insufficiency; distal Xp22.33 deletions involving SHOX cause short stature without the full syndrome Gravholt 2024
Klinefelter syndrome 47,XXY; expected prevalence 152 per 100,000 newborn males; about 38% diagnosed Infertility is a hallmark Ridder 2023
47,XYY syndrome Expected prevalence 98 per 100,000 newborn males; about 18% diagnosed Fertility appears reduced Ridder 2023
Trisomy X 47,XXX; about 1 in 1,000 female births; about 10% diagnosed; postzygotic nondisjunction in about 20% Tall stature and premature ovarian failure; risk rises with maternal age Tartaglia 2010
Triploidy 69 chromosomes; diandric (paternal) 44.9% overall, 64.3% of losses at 11–14 weeks and 27.8% of pregnancies beyond 14 weeks Most diandric triploids are lost in the first trimester, and digynic triploidy predominates later; origin determined by QF-PCR or MS-MLPA Massalska 2021

Microdeletion and microduplication syndromes

Classic recurrent deletion syndromes and their cytobands.

Syndrome Cytoband (hg18 critical region) Reciprocal duplication or related condition Source
1p36 deletion syndrome 1pter-p36.31 1p36 duplication involving GABRD Weise 2012
Wolf–Hirschhorn syndrome 4pter-p16.3 4p16.3 microduplication Weise 2012
Cri-du-chat syndrome 5p15.2-p15.33 No reciprocal duplication listed Weise 2012
Williams–Beuren syndrome 7q11.23 7q11.23 duplication Weise 2012; Nevado 2014
Prader–Willi and Angelman syndromes 15q11.2-q13.1 15q duplication Weise 2012
Miller–Dieker syndrome 17p13.3 Miller–Dieker microduplication Weise 2012
Smith–Magenis syndrome 17p11.2 Potocki–Lupski syndrome Weise 2012
DiGeorge (22q11.2 deletion) syndrome 22q11.21-q11.23 22q11.2 microduplication Weise 2012

Prenatal and products-of-conception cytogenetics

  • Chorionic villus sampling and placental mosaicism. In about 2% of viable pregnancies studied by CVS at 9 to 11 weeks, the abnormality, most often a trisomy, is confined to the placenta (Kalousek 1996). Confined placental trisomy is associated with fetal uniparental disomy and intrauterine growth restriction (Kalousek 1996).
  • Maternal cell contamination (MCC). Maternal blood is visible in 1% to 2% of amniotic fluid samples and in up to 38% of pelleted amniocytes after centrifugation. MCC testing compares polymorphic STR loci in maternal and fetal DNA and strictly requires only a maternal blood or buccal sample (Nagan 2011). Maternal blood cells senesce in culture, prolonged culture can allow maternal fibroblast overgrowth, and discarding the first draw of amniotic fluid reduces contamination. Inconclusive results are confirmed on a backup cultured specimen (Nagan 2011).
  • Stillbirth and pregnancy loss tissue. In 532 stillbirths, microarray gave a result in 87.4% and karyotype in 70.5%, because 29.5% of karyotypes failed in every tissue tested. Microarray detected aneuploidy or pathogenic CNVs in 8.3% compared with 5.8% for karyotype, a relative increase of 41.9% (Reddy 2012).
  • Cell-free DNA screening. Noninvasive prenatal screening performance and confirmatory testing are taught in Reproductive Endocrinology and Pregnancy Screening: Gonadal Hormones, hCG and Prenatal Testing.
  • Turner syndrome in pregnancy. Women with 45,X/46,XX mosaicism who conceive spontaneously are offered prenatal diagnostic testing (Gravholt 2024).

Cancer cytogenetics as a laboratory method

Recurrent abnormalities detected by cytogenetic methods.

Neoplasm Abnormality and fusion Preferred cytogenetic method Related page Source
Chronic myeloid leukemia t(9;22)(q34;q11.2) in at least 90%; complex or cryptic variants in the rest; BCR::ABL1 Dual-color dual-fusion FISH and karyotype Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms Wolff 2007
B-lymphoblastic leukemia Cryptic t(12;21); ETV6::RUNX1 Single-fusion extra-signal FISH B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease Wolff 2007
Acute leukemias with KMT2A rearrangement More than 80 partner genes Break-apart FISH Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk Wolff 2007
Acute promyelocytic leukemia PML::RARA Dual-color dual-fusion FISH Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk Wolff 2007; Khoury 2022
Classic follicular lymphoma t(14;18)(q32;q21); IGH::BCL2 Dual-color dual-fusion FISH Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia Alaggio 2022; Wolff 2007
Mantle cell lymphoma t(11;14)(q13;q32); IGH::CCND1 in at least 95%; occasional IGK or IGL partners FISH for CCND1 rearrangement Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia Alaggio 2022
Ewing sarcoma and round cell sarcomas EWSR1 fusions with ETS and non-ETS partners; CIC and BCOR alterations Formal demonstration of the fusion gene Molecular and Ancillary Testing of Soft Tissue FNA Material Sbaraglia 2021

Complex karyotype definitions and myeloid risk groups are taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition and Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk. Large B-cell lymphoma MYC, BCL2 and BCL6 FISH is taught in Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging, the myeloma FISH panel in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases and TFE3 FISH in renal tumors in Renal Cell Carcinoma and Oncocytic Renal Tumors.

Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening

Scope. Interpretation of a detected variant uses inheritance and risk calculation, the ACMG/AMP five-class germline system with its ClinGen refinements and Bayesian point scale, the AMP/ASCO/CAP four-tier somatic system and the ClinGen/CGC/VICC oncogenicity standard.

Related page: Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation (NGS methods, depth, HGVS nomenclature and validation) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (ACMG/ClinGen CNV classification, microarray and karyotype) Related page: Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome (cystic fibrosis, fragile X, imprinting, mitochondrial and hereditary cancer testing) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (germline findings on tumor sequencing and tumor-agnostic biomarkers) Related page: Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs (pharmacogenomic recommendations) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (newborn screening programs)

Inheritance patterns and modifiers of phenotype

Genotype states assessed in variant interpretation.

Pattern Genotype that causes disease Interpretation point Source
Autosomal dominant Heterozygous A variant seen in a healthy adult heterozygote for a fully penetrant early-onset dominant disorder is strong benign evidence (BS2) Richards 2015
Autosomal recessive Homozygous, or two variants in trans Detection in trans with a pathogenic variant is moderate pathogenic evidence (PM3) and requires parental or offspring testing to determine phase Richards 2015
X-linked Hemizygous in males A healthy hemizygous adult argues against pathogenicity for an early-onset, fully penetrant disorder (BS2) Richards 2015
Mitochondrial Heteroplasmic or homoplasmic mitochondrial DNA variant Heteroplasmy detection sets the NGS depth requirement taught in Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation Jennings 2017
De novo Variant absent in both parents Strong evidence (PS2) only when both maternity and paternity are confirmed; a variant assumed de novo without confirmation is moderate evidence (PM6) Richards 2015
X-linked dominant Hemizygous males and heterozygous females are affected; females may be less severely affected No male-to-male transmission MedlinePlus Genetics
Y-linked Variant on the Y chromosome Passed only from father to son, for example Y chromosome infertility MedlinePlus Genetics
  • X-linked inheritance without a dominant or recessive label. Because many X-linked disorders are not clearly dominant or recessive, some experts classify them simply as X-linked (MedlinePlus Genetics).

Transmission risks by inheritance pattern (MedlinePlus Genetics risk assessment).

Pattern Risk to offspring with each pregnancy
Autosomal dominant An affected heterozygous parent transmits the variant to each child with a 50% chance; a de novo variant gives unaffected parents an affected child
Autosomal recessive Two carrier parents: 25% affected, 50% unaffected carrier and 25% noncarrier; one carrier and one noncarrier parent: no affected child and a 50% chance of a carrier child
X-linked dominant An affected father transmits the disorder to all daughters and no sons; an affected mother transmits it to each child with a 50% chance
X-linked recessive All sons of an affected father are unaffected and all daughters are carriers; with a carrier mother each son has a 50% chance of being affected and each daughter a 50% chance of being a carrier
Y-linked Only males are affected, and all sons of an affected father inherit the variant
Mitochondrial An affected mother transmits mitochondrial DNA variants to all of her children; fathers transmit them to no child

The risk is the same for every pregnancy, whatever the outcome of earlier pregnancies (MedlinePlus Genetics risk assessment).

Hardy–Weinberg equilibrium and Bayesian risk calculation

  • Carrier frequency from disease incidence. With a disease allele frequency q, the incidence of an autosomal recessive disease is q². The carrier frequency is 2(1 − q)q, approximately 2q when q is small (Ogino 2004). For an incidence of 1 in 2,500, q = 1/50 and the carrier frequency is about 1/25.
  • Assumptions. Hardy–Weinberg calculations assume equilibrium, and random mating is a basic prerequisite (Ogino 2004). The calculation applies to a person without a family history, who is representative of the general population (Ogino 2004).
  • Bayesian table. Each hypothesis (carrier, noncarrier) has a prior probability, a conditional probability of the observed information, a joint probability (prior × conditional) and a posterior probability (joint ÷ sum of joints) (Ogino 2004).

Bayesian carrier-risk calculations (Ogino 2004).

Step X-linked carrier with three unaffected sons Sibling of a person with cystic fibrosis who tests negative on a panel detecting 90% of alleles
Prior: carrier 1/2 2/3 (an unaffected sibling of an affected child)
Prior: noncarrier 1/2 1/3
Conditional: carrier (1/2)³ = 1/8 1/10 (probability a carrier tests negative)
Conditional: noncarrier 1 1
Joint: carrier 1/16 2/3 × 1/10 = 1/15
Joint: noncarrier 1/2 1/3
Posterior carrier risk 1/16 ÷ 9/16 = 1/9 1/15 ÷ (1/15 + 1/3) = 1/6
  • Risk to a pregnancy. Before testing, the risk that the fetus of the sibling (carrier probability 2/3) and an unrelated partner (carrier probability 1/25) is affected is 2/3 × 1/25 × 1/4 = 1/150 (Ogino 2004).
  • Residual risk after negative carrier screening. Residual carrier risk equals the population carrier frequency × (1 − detection rate). The residual risk is never zero (Gregg 2021).

ACMG/AMP germline sequence variant classification

  • Five classes. Pathogenic, likely pathogenic, uncertain significance, likely benign and benign. "Likely pathogenic" and "likely benign" mean greater than 90% certainty that a variant is disease-causing or benign (Richards 2015).
  • Weighting. Pathogenic criteria are very strong (PVS1), strong (PS1–PS4), moderate (PM1–PM6) or supporting (PP1–PP5). Benign criteria are stand-alone (BA1), strong (BS1–BS4) or supporting (BP1–BP7). Numbering within a category carries no difference in weight (Richards 2015).
  • Uncertain significance. A variant is classified as uncertain significance when the criteria for another class are unmet or when benign and pathogenic criteria contradict each other (Richards 2015).

ACMG/AMP evidence criteria (Richards 2015).

Code Strength Criterion
PVS1 Very strong Null variant (nonsense, frameshift, canonical ±1 or 2 splice site, initiation codon, single or multiexon deletion) in a gene where loss of function is a known disease mechanism
PS1 Strong Same amino acid change as an established pathogenic variant, regardless of nucleotide change
PS2 Strong De novo with maternity and paternity confirmed, in a patient with the disease and no family history
PS3 Strong Well-established functional studies show a damaging effect
PS4 Strong Prevalence in affected individuals significantly increased over controls (odds ratio or relative risk above 5.0, confidence interval excluding 1.0)
PM1 Moderate Mutational hot spot or critical functional domain without benign variation
PM2 Moderate Absent from controls, or at extremely low frequency for recessive disorders, in population databases
PM3 Moderate For recessive disorders, detected in trans with a pathogenic variant
PM4 Moderate Protein length change from in-frame indel in a nonrepeat region, or stop-loss
PM5 Moderate Novel missense change at a residue where a different pathogenic missense change is known
PM6 Moderate Assumed de novo without confirmation of maternity and paternity
PP1 Supporting Cosegregation with disease in multiple affected family members
PP2 Supporting Missense variant in a gene with a low rate of benign missense variation where missense is a common mechanism
PP3 Supporting Multiple computational lines of evidence support a deleterious effect; used only once
PP4 Supporting Phenotype or family history highly specific for a single-gene disease
PP5 Supporting Reputable source reports pathogenic without evidence available to the laboratory
BA1 Stand-alone Allele frequency above 5% in large population databases
BS1 Strong Allele frequency greater than expected for the disorder
BS2 Strong Observed in a healthy adult with the genotype expected to cause a fully penetrant early-onset disorder
BS3 Strong Well-established functional studies show no damaging effect
BS4 Strong Lack of segregation in affected family members
BP1 Supporting Missense variant in a gene where primarily truncating variants cause disease
BP2 Supporting In trans with a pathogenic variant for a fully penetrant dominant disorder, or in cis with a pathogenic variant
BP3 Supporting In-frame indel in a repetitive region without known function
BP4 Supporting Multiple computational lines of evidence suggest no impact; used only once
BP5 Supporting Found in a case with an alternate molecular basis for disease
BP6 Supporting Reputable source reports benign without evidence available to the laboratory
BP7 Supporting Synonymous variant with no predicted splice impact at a poorly conserved nucleotide

ACMG/AMP rules for combining criteria (Richards 2015).

Class Combinations
Pathogenic (i) 1 very strong with ≥1 strong, ≥2 moderate, 1 moderate and 1 supporting, or ≥2 supporting; (ii) ≥2 strong; (iii) 1 strong with ≥3 moderate, 2 moderate and ≥2 supporting, or 1 moderate and ≥4 supporting
Likely pathogenic 1 very strong and 1 moderate; 1 strong and 1–2 moderate; 1 strong and ≥2 supporting; ≥3 moderate; 2 moderate and ≥2 supporting; 1 moderate and ≥4 supporting
Benign 1 stand-alone; ≥2 strong
Likely benign 1 strong and 1 supporting; ≥2 supporting

ClinGen refinements of ACMG/AMP criteria

Original strength and ClinGen Sequence Variant Interpretation refinement.

Criterion Richards 2015 ClinGen refinement
PVS1 Very strong for null variants where loss of function is a disease mechanism; no decision pathway Decision tree by variant type (nonsense or frameshift, splice site, initiation codon, deletion, duplication) assigns PVS1, PVS1_Strong, PVS1_Moderate or PVS1_Supporting. NMD is not predicted for premature stops in the 3′-most exon or the 3′-most 50 nucleotides of the penultimate exon. Without NMD, removal of more than 10% of the protein supports PVS1_Strong and less than 10% supports PVS1_Moderate (Abou Tayoun 2018)
PS3 and BS3 Strong for "well-established" functional studies, without criteria for evaluating assays Four-step framework: define the disease mechanism, evaluate general classes of assay, evaluate the specific assay instance and apply evidence to the variant. A minimum of 11 total pathogenic and benign variant controls is needed to reach moderate-level evidence without rigorous statistical analysis (Brnich 2019)
PP3 and BP4 Supporting; consensus of multiple predictors; used once Calibrated score intervals for single tools convert scores to supporting, moderate or strong evidence. For most situations one genome-wide tool that can reach strong evidence for pathogenicity and moderate for benignity is used, such as BayesDel, MutPred2, REVEL or VEST4 (Pejaver 2022)
  • Validation of the PVS1 decision tree. Seven disease-specific groups showed 89% agreement with the refined PVS1 recommendation on 56 loss-of-function variants (Abou Tayoun 2018).
  • REVEL calibrated thresholds. Pathogenic evidence: supporting 0.644 to <0.773, moderate 0.773 to <0.932, strong ≥0.932. Benign evidence: supporting >0.183 to 0.290, moderate >0.016 to 0.183, strong >0.003 to 0.016, very strong ≤0.003. The combined strength of PP3 and PM1 is capped at strong (4 points) (Pejaver 2022).
  • Gene-specific specifications. ClinGen Variant Curation Expert Panels develop gene- and disease-specific rule specifications, and their functional assay evaluations informed the PS3/BS3 recommendations (Brnich 2019).

Bayesian framework and point scale for germline classification

  • Bayesian model. The ACMG/AMP criteria translate into a naive Bayesian classifier with a prior probability of pathogenicity of 0.10 and odds of pathogenicity of 350 for very strong evidence. Likely pathogenic corresponds to a posterior probability above 0.90 and pathogenic to above 0.99. Likely benign corresponds to 0.001 to below 0.10 and benign to below 0.001 (Tavtigian 2018).
  • Internal consistency. Only 2 of the 18 ACMG/AMP combining rules were inconsistent with the framework: Likely Pathogenic (i), 1 very strong and 1 moderate, reached pathogenic, and Pathogenic (ii), ≥2 strong, reached only likely pathogenic. Mixed pathogenic and benign evidence can yield likely pathogenic, likely benign or uncertain significance (Tavtigian 2018).

Tavtigian point scale (Tavtigian 2020).

Strength Pathogenic points Benign points
Supporting 1 −1
Moderate 2 −2
Strong 4 −4
Very strong 8 −8
Classification Point total
Pathogenic ≥10
Likely pathogenic 6 to 9
Uncertain significance 0 to 5
Likely benign −1 to −6
Benign ≤ −7

Points are proportional to the logarithm of the odds of pathogenicity and are therefore additive. The point scale assumes a narrow range of prior probabilities and does not show the underlying Bayesian calculation (Tavtigian 2020).

AMP/ASCO/CAP somatic variant tiers

Interpretation of somatic variants focuses on their impact on clinical care, whereas germline interpretation focuses on pathogenicity for a specific disease (Li 2017).

Evidence levels (Li 2017).

Level Therapeutic Diagnostic Prognostic
A Predicts response or resistance to an FDA-approved therapy for the specific tumor type, or is included in professional guidelines for that tumor type Included in professional guidelines as diagnostic for the tumor type Included in professional guidelines as prognostic for the tumor type
B Predicts response or resistance in the specific tumor type in well-powered studies with expert consensus Diagnostic significance in well-powered studies with expert consensus Prognostic significance in well-powered studies with expert consensus
C Predicts response or resistance to a therapy approved by FDA or professional societies for a different tumor type, or serves as inclusion criterion for clinical trials Diagnostic significance from multiple small studies Prognostic significance from multiple small studies
D Plausible therapeutic significance from preclinical studies May assist diagnosis based on small studies or a few case reports May assist prognosis based on small studies or a few case reports

Somatic tiers (Li 2017).

Tier Definition Evidence
I Variants of strong clinical significance Level A or B
II Variants of potential clinical significance Level C or D
III Variants of unknown clinical significance; not observed at significant frequency in population databases Somatic variants in cancer genes reported in the same or other cancer types without known clinical significance, or not reported in any cancer
IV Benign or likely benign; mostly rare germline variants Minor allele frequency of at least 1% in the general population or high in some ethnic populations; mostly nonmosaic VAF near 50% or 100%

Somatic reporting requirements (Li 2017).

ClinGen/CGC/VICC oncogenicity classification

  • Purpose. The AMP/ASCO/CAP guidelines address diagnostic, prognostic and therapeutic implications and describe data types relevant to oncogenicity without giving a systematic set of rules to classify it. The ClinGen/CGC/VICC standard classifies whether a somatic variant confers growth and survival advantages to tumor cells (Horak 2022).
  • Categories. Oncogenic, likely oncogenic, variant of uncertain significance, likely benign and benign (Horak 2022).
  • Points. Evidence is weighted very strong (8 points), strong (4), moderate (2) or supporting (1) for oncogenicity and with negative points for benign impact, combined with a point system based on Tavtigian (Horak 2022). The standard was validated on 94 somatic variants in ten cancer-related genes (Horak 2022).

Examples of oncogenicity criteria (Horak 2022).

Code Strength Criterion
OVS1 Very strong (8) Null variant in a bona fide tumor suppressor gene
OS1 Strong Same amino acid change as an established oncogenic variant regardless of nucleotide change
OS3 Strong Hotspot in cancerhotspots.org with at least 50 samples with a somatic variant at the position and at least 10 with the same amino acid change
OM2 Moderate In-frame indel in a known oncogene or tumor suppressor, or stop-loss in a known tumor suppressor
OM4 Moderate Missense change at a residue where a different oncogenic missense change is documented
SBVS1 Very strong benign (−8) Minor allele frequency above 5% in gnomAD in any of five general continental populations
SBS1 Strong benign (−4) Minor allele frequency above 1% in gnomAD in any of five general continental populations

For a variant in a hereditary cancer gene, ClinGen germline expert panel guidance sets population frequency cutoffs that account for disease prevalence (Horak 2022). Germline findings on tumor sequencing are taught in Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing.

Secondary findings in exome and genome sequencing

  • Definition. Secondary findings are clinically relevant results unrelated to the condition for which sequencing was ordered (Botkin 2015).
  • ACMG SF v3.3 (current). Three genes were added: ABCD1 (X-linked adrenoleukodystrophy), CYP27A1 (cerebrotendinous xanthomatosis) and PLN (cardiomyopathy). GCK, RUNX1 and SLC4A1 were considered and not added, and a decision on ADA2 was deferred for lack of penetrance data in genomically ascertained populations. The proposed list went to the ACMG Board of Directors in October 2024, and the Board approved the statement on February 24, 2025 (Lee 2025).
  • ACMG SF v3.2 (previous). CALM1, CALM2 and CALM3 (long QT syndrome and catecholaminergic polymorphic ventricular tachycardia) were added (Miller 2023).
  • Versioning. Minor revisions that add or remove one or a few genes without a policy change increase the number after the decimal point (Miller 2023). ACMG members may nominate genes for addition or removal (Lee 2025).
  • Testing of minors. Testing for adult-onset conditions in children without timely medical benefit was historically deferred to adulthood. Predictive or predispositional testing of children for adult-onset conditions can be justified in specific cases requested by families after informed deliberation, when not clearly inconsistent with the child's welfare. Diagnostic testing, predictive testing for childhood-onset conditions, pharmacogenetic testing and testing of children with cancer to inform diagnosis or therapy are appropriate (Botkin 2015).
  • Huntington disease model. Only a minority of at-risk adults choose predictive testing for Huntington disease (Botkin 2015).
  • Genetic Information Nondiscrimination Act (GINA). GINA applies to health insurance and employment. It does not cover life, long-term care or disability insurance, does not apply to employers with fewer than 15 employees and does not apply to the military; federal employees have protection by executive order. In a survey, 92.6% of respondents with high subjective knowledge of GINA did not know that it excludes life, long-term care and disability insurance (Lenartz 2021).

Exome and genome sequencing

Carrier screening

  • Previous ACMG position (2013). Expanded carrier screening panels must disclose the basis for selecting disorders, inform patients completely about mild, variable, low-penetrance and adult-onset disorders so they can opt out, and explain residual risk after negative results (Grody 2013). Ethnicity-based screening for Ashkenazi Jewish patients and panethnic screening for cystic fibrosis and spinal muscular atrophy were established examples (Grody 2013).
  • Current ACMG practice resource (2021). All pregnant patients and those planning a pregnancy are offered Tier 3 carrier screening for autosomal recessive and X-linked conditions (Gregg 2021).

ACMG 2021 carrier screening tiers (Gregg 2021).

Tier Scope
Tier 1 Previous ACMG and ACOG recommendations; ethnic- and population-neutral screening for cystic fibrosis and spinal muscular atrophy
Tier 2 ACOG-based: conditions with a severe or moderate phenotype and a carrier frequency of at least 1/100
Tier 3 Carrier frequency of at least 1/200 in any ethnic group with reasonable representation in the United States, plus X-linked conditions; 97 autosomal recessive genes
Tier 4 Genes less common than Tier 3, with no lower carrier frequency limit

ACMG/AMP germline evidence combiner with Bayesian points

Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome

Definition. Molecular testing for inherited disease detects germline sequence variants, copy-number changes, repeat expansions, methylation abnormalities and mitochondrial DNA variants that cause or predispose to disease. The method depends on the variant type: repeat sizing for expansion disorders, methylation analysis for imprinting disorders, copy-number methods for SMN1 and DMD, heteroplasmy measurement for mitochondrial DNA and sequencing with deletion analysis for hereditary cancer genes (Biancalana 2015; Beygo 2019; Milligan 2022; Chavez-Ecos 2026; Parikh 2015; Mandelker 2019).

Related page: Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening (inheritance, Hardy–Weinberg and Bayesian risk, ACMG/AMP classification, carrier screening tiers) Related page: Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA (methylation-specific PCR, MS-MLPA and MLPA principles) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (15q11–q13 deletion by FISH and microarray; uniparental disomy on SNP array) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome genetics and cancer risks, MMR immunohistochemistry interpretation, MLH1 promoter methylation and BRAF V600E triage, Lynch-like syndrome, CMMRD, polyposis genes) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (cystic fibrosis newborn screening with IRT and sweat chloride; SMA newborn screening; biochemical evaluation of mitochondrial disorders) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (indications for factor V Leiden and prothrombin testing; APC resistance assays) Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (hereditary hemochromatosis and Wilson disease in the liver) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (α-thalassemia deletion testing and globin gene sequencing) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (germline findings on tumor sequencing; MSI and MMR assays for immunotherapy)

Cystic fibrosis: CFTR testing methods and carrier panels

  • CFTR gene. CFTR is located at 7q31.2 and contains 27 coding exons. The reference mRNA and protein sequences are NM_000492 and NP_000483 (Deignan 2020).
  • History of the panel. In 2001 cystic fibrosis (CF) became the first target of pan-ethnic universal carrier screening by molecular methods. The ACMG-23 variant panel was derived from an original 25-variant panel produced by two NIH consensus conferences (1997 and 1998) (Deignan 2020).
  • Two acceptable approaches (2020 technical standard). A laboratory may use classification-based targeted testing, in which the ACMG-23 panel is the minimum variant list, or classification-based reporting. Classification-based reporting assesses at least all exonic coding regions and ±2 bp of the splice junctions and reports every pathogenic and likely pathogenic variant for classic CF. Benign and likely benign variants are not reported (Deignan 2020).
  • Intronic variants. c.2657+5G>A (legacy 2789+5G>A) and c.3718–2477C>T (legacy 3849+10kbC>T) were in the ACMG-23 panel and are reported for every CFTR sequencing indication. A method that cannot detect them is stated in the report (Deignan 2020).
  • Variant classification. All CFTR variants are classified with the ACMG sequence-variant recommendations. The CFTR2 project cannot assign about 5% of variants to disease-causing or non-disease-causing categories (Deignan 2020). Variants of varying clinical consequence are reported for diagnostic indications when comprehensive methods are used (Deignan 2020).
  • Deletion and duplication testing. MLPA and exon-targeted array CGH detect single-exon copy-number changes in CFTR (Deignan 2020).
  • Orthogonal confirmation. Sanger sequencing is a common method for confirming variants found by NGS. Orthogonal confirmation is not usually applied when the first test is not NGS (Deignan 2020).

CFTR carrier panel recommendations, current and previous.

Item Current rule Previous rule Source
Minimum targeted panel ACMG 2023 position statement: a 100-variant CFTR panel ACMG-23 panel, retained as the minimum in the 2020 technical standard ("not increased at this time") Deignan 2023, cited in Xiao 2026; Deignan 2020
ACOG minimum for all pregnant or preconception patients Targeted analysis of at least 23 pathogenic variants Same Santoli 2025
Full CFTR sequencing Clinical evidence of CF without confirmatory testing, males with congenital bilateral absence of the vas deferens and infants with a positive newborn screen Same Santoli 2025
Family history with a known familial variant Targeted testing for that variant Same Santoli 2025

Intron 9 poly-T and TG tracts. The p.Arg117His (c.350G>A, R117H) variant shows variable expressivity that depends on the poly-T tract in intron 9: c.1210–12T[5], T[7] or T[9] (Deignan 2020).

Genotype Usual consequence Source
p.Phe508del (c.1521_1523delCTT) Occurs almost completely in cis with 9T Deignan 2020
R117H and 5T in cis with a CF-causing variant in trans Generally nonclassic CF Deignan 2020
R117H and 7T in cis with a CF-causing variant in trans Asymptomatic to congenital absence of the vas deferens (CAVD) in males; very rarely nonclassic CF Deignan 2020
5T with 11TG in cis, with a CF-causing variant in trans Rarely increased risk of CAVD Deignan 2020
5T with 12TG or 13TG in cis, with a CF-causing variant in trans Risk of CAVD; rarely nonclassic CF Deignan 2020
  • 5T frequency. One in ten individuals carries a 5T variant, so 5T is interpreted with the adjacent TG count (Deignan 2020).
  • Reporting. For diagnostic indications, R117H status and at least the associated poly-T tract are reported. In carrier screening, poly-T status is reported when R117H is detected (Deignan 2020).
  • Carrier frequency by population. With 32 pathogenic variants examined in a US population, the CF carrier frequency ranged from 1/28 in people described as "Caucasian" to 1/105 in "African American" and 1/261 in "Asian" individuals (Gregg 2021).

Fragile X syndrome: FMR1 CGG repeat testing

  • Gene and mechanism. FMR1 is at Xq27.3, has 17 exons and encodes FMRP. A polymorphic CGG repeat in the 5′ untranslated region is pure or interspersed with 1–4 AGG triplets in its 5′ region. Instability depends on the length of uninterrupted CGG repeat (Biancalana 2015).
  • Full mutation. More than about 200 CGG repeats with abnormal methylation of the repeat, CpG island and promoter cause loss of FMR1 mRNA and FMRP. This mechanism accounts for 99% of reported fragile X syndrome (FXS). All males and about 50% of females with a full mutation are affected (Biancalana 2015).
  • Premutation phenotypes. Premutations cause fragile X-associated primary ovarian insufficiency (FXPOI) in females and fragile X-associated tremor/ataxia syndrome (FXTAS) in males and females through RNA overexpression and toxicity. About 21% of female premutation carriers have primary ovarian insufficiency with menopause before age 40 years, compared with 1% in the general population (Biancalana 2015).
  • Maternal expansion. A premutation transmitted by a female can expand to a full mutation, and the risk rises with premutation size. The risk exceeds 98% for alleles with more than 100 repeats. The smallest allele reported to expand to a full mutation in one generation had 56 CGG repeats without AGG interruptions (Biancalana 2015).
  • Paternal transmission. Daughters of a male premutation carrier inherit a premutation. Expansion to a full mutation through a male has not been seen, and prenatal testing is not indicated for the partner of a male premutation carrier (Biancalana 2015).
  • AGG interruptions. The number of AGG interruptions and the length of uninterrupted 3′ CGG repeat correlate with instability on transmission and refine risk estimates for intermediate and small premutation alleles (Biancalana 2015).
  • Mosaicism. Size mosaicism arises from mitotic instability in the early embryo before methylation. Mosaicism for a full mutation with a normal allele (MoMN) or with a premutation and a normal allele (MoMPN) was found in about 1% of FXS males in two laboratories. Unmethylated or partly methylated full mutations (methylation mosaics) occur in some high-functioning males (Biancalana 2015).

FMR1 CGG repeat categories. Sizing error up to ±5% of total repeat size is accepted (Biancalana 2015).

Category Repeats Methylation Phenotype Transmission Source
Normal <45 (most common 29 or 30) Unmethylated on the active X Normal Transition to a full mutation never reported Biancalana 2015
Intermediate (gray zone) 45–54 Unmethylated Normal Possible instability; expansion to a full mutation seen over two generations only; genetic counseling of relatives recommended at ≥50 repeats Biancalana 2015
Premutation 55 to about 200 Unmethylated FXPOI in females; FXTAS in males and females Unstable; risk of a full mutation in one generation through a female, proportional to size Biancalana 2015
Full mutation More than about 200 Abnormal methylation FXS in all males and about 50% of females Arises only from premutations Biancalana 2015

Fragile X test methods.

Method What it detects Limitations Source
PCR with flanking primers Accurate sizing of normal, intermediate and premutation alleles Large CG-rich alleles fail to amplify; a single peak in a female is either homozygosity or an unamplified expansion; mosaic males with a normal allele can be missed; a SNP or deletion under a primer causes allele dropout Biancalana 2015
Triplet-repeat primed PCR (TP-PCR) Expansions across the full range, shown as a ladder of products Repeat-flanking deletions caused false negatives with a 3′ TP-PCR in the DMPK gene; combined 5′ and 3′ TP-PCR reduces this Biancalana 2015
Methylation-sensitive PCR and TP-MS-PCR Repeat size with methylation status Interpretation in females complicated by the methylated normal allele on the inactive X Biancalana 2015
Southern blot (EcoRI with a methylation-sensitive enzyme such as EagI or NruI) All expansions with methylation status; mosaic patterns Premutation sizing requires PCR; EcoRI alone gives a 5.2-kb normal fragment, and the unmethylated normal allele gives about 2.8 kb after double digestion Biancalana 2015
MS-MLPA Methylation of the promoter Validated for male samples only Biancalana 2015
  • Distinguishing a large premutation from a small full mutation. Alleles near 200 ± 30 repeats are separated by methylation status. Premutations are unmethylated on the active X, and full mutations usually are methylated (Biancalana 2015).
  • Abnormal karyotypes. The sex of the patient and karyotypes such as XXX, XXY and XXYY are considered when a PCR result on the X chromosome is interpreted (Biancalana 2015).
  • Report wording. HGVS nomenclature may be used, but the report also states the number of CGG repeats and the category in words (Biancalana 2015).
  • ACMG standard, current and previous. The ACMG fragile X technical standard was revised in 2021, the fourth update of the original 2001 standard after revisions in 2005 and 2013. The 2021 revision adds triplet repeat-primed and methylation-specific PCR to the methods (Spector 2021).

Other repeat expansion disorders

Repeat ranges for common expansion disorders.

Disorder Gene and location Repeat and position Normal Pathogenic Inheritance Source
Huntington disease HTT, 4p16.3 CAG, exon 1 (polyglutamine) 6–26 36–39 reduced penetrance; ≥40 full penetrance AD Losekoot 2013
Myotonic dystrophy type 1 DMPK, 19q13.3 CTG, 3′ UTR 5–35 51–150 none, minimal or classical DM; >150 classical, juvenile or congenital DM AD Kamsteeg 2012
Myotonic dystrophy type 2 CNBP, 3q21 CCTG, intron 1 Up to 26 CCTG units About 75 to over 11 000 units (mean 5000) AD Kamsteeg 2012
Friedreich ataxia FXN, 9q21.11 GAA, intron 5–34 ≥66–1300 AR Depienne 2021
Spinal and bulbar muscular atrophy AR, Xq12 CAG, coding 9–36 ≥38–68 XLR Depienne 2021
Spinocerebellar ataxia type 1 ATXN1, 6p22 CAG, coding 6–38 ≥39–88 AD Depienne 2021
Spinocerebellar ataxia type 2 ATXN2, 12q24 CAG, coding 13–31 ≥32–500 AD Depienne 2021
Spinocerebellar ataxia type 3 ATXN3, 14q32 CAG, coding 12–44 ≥55–87 AD Depienne 2021
Spinocerebellar ataxia type 6 CACNA1A, 19p13 CAG, coding 4–18 ≥20–33 AD Depienne 2021
Spinocerebellar ataxia type 7 ATXN7, 3p21 CAG, coding 4–33 ≥37–460 AD Depienne 2021
Frontotemporal dementia and ALS C9orf72, 9p21.2 GGGGCC, 5′ UTR or intron 3–25 >30 AD Depienne 2021

Huntington disease allele categories and interpretation (EMQN/CMGS).

CAG repeats Category Diagnostic test Predictive test Offspring Source
6–26 Normal Diagnosis not confirmed or excluded Will not develop HD No increased risk Losekoot 2013
27–35 Intermediate (mutable normal) Diagnosis not confirmed or excluded Will not develop HD Increased risk (<10%); general-population intermediate alleles carry <1% Losekoot 2013
36–39 Incomplete penetrance Diagnosis confirmed May or may not develop HD Increased risk Losekoot 2013
≥40 Complete penetrance Diagnosis confirmed Will develop HD Increased risk Losekoot 2013
  • HD intermediate alleles. Expansion of an intermediate allele into the disease range is estimated at 0.1–1% per generation. New mutations arise from intermediate alleles, mainly through paternal transmission (Losekoot 2013).
  • HD anticipation. Anticipation in HD occurs more often through paternal transmission because the CAG repeat expands during spermatogenesis (Losekoot 2013).
  • HD sizing. PCR products containing CAG repeats migrate anomalously, so conventional size ladders are unreliable. Controls of known size at the category borders and a large expansion (>60 repeats) are used for sizing (Losekoot 2013). The ACMG HD technical standard (2004) has a 2021 addendum (Potter 2004; Bean 2021).
  • DM1 anticipation and parental sex. CTG repeat size correlates with severity and earlier onset, and the repeat increases in successive generations. Parental sex affects intergenerational instability once the repeat exceeds 150. Congenital DM1 is transmitted almost exclusively by the mother (Kamsteeg 2012).
  • DM1 and DM2 testing. Conventional PCR with fragment analysis is the first step. When only one allele size is seen, TP-PCR or Southern blotting of genomic DNA or long-range PCR products follows. Clinical sensitivity and specificity of repeat expansion detection exceed 99% for DM1 and DM2 (Kamsteeg 2012). In TP-PCR one primer is outside the repeat, one is within the repeat and is added in limiting amounts, and a fluorescently labeled universal primer anneals to the tail of the repeat primer (Kamsteeg 2012).
  • Prenatal DM1. Maternal DNA is analyzed with the fetal sample to exclude maternal cell contamination (Kamsteeg 2012).

Imprinting disorders

Prader–Willi and Angelman syndromes: mechanisms and recurrence risks (EMQN/ACGS 2019).

Mechanism Prader–Willi syndrome (proportion; recurrence) Angelman syndrome (proportion; recurrence) Source
De novo 15q11–q13 deletion Paternal chromosome; 70–75%; <1% Maternal chromosome; 75%; <1% Beygo 2019
Uniparental disomy 15 Maternal UPD; 25–30%; <1% Paternal UPD; 1–2%; <1% Beygo 2019
Imprinting defect without imprinting center deletion 1%; <1% 3%; <1% Beygo 2019
Imprinting center deletion About 10–15% of imprinting defects; 50% if non-mosaic in the father About 10–15% of imprinting defects; 50% if non-mosaic in the mother Beygo 2019
UBE3A pathogenic variant Not a cause of PWS 5–10%; 50% if non-mosaic in the mother Beygo 2019
No identifiable molecular abnormality Not listed for PWS 10–15%; recurrence unknown (up to 50%) Beygo 2019
  • Methylation testing first. DNA methylation analysis of the 15q11–q13 critical region detects more than 99% of PWS and about 80% of AS. A normal methylation pattern excludes PWS with a sensitivity of about 99% (Beygo 2019).
  • Follow-up after abnormal methylation. The deletion, UPD and imprinting defect are distinguished by copy-number analysis and parental microsatellite or SNP studies. Imprinting defects show biparental inheritance of chromosome 15 markers with an abnormal methylation pattern (Beygo 2019).
  • Mosaic imprinting defects. More than 40% of AS imprinting defects without an imprinting center deletion show partial hypomethylation. These arise after fertilization and carry no increased recurrence risk (Beygo 2019).
  • AS with normal methylation. UBE3A analysis follows when clinical suspicion remains (Beygo 2019).
  • Deletion size. The common del(15)(q11q13) extends about 5–7 Mb. In PWS it is always on the paternal chromosome and in AS on the maternal chromosome (Beygo 2019).

Beckwith–Wiedemann spectrum (11p15). A molecular defect is found in about 80% of patients (Brioude 2018).

Mechanism Frequency Recurrence Source
Loss of methylation at maternal IC2 (KCNQ1OT1) About 50% Generally low; one-third of IC2 loss cases have multilocus imprinting disturbance Brioude 2018
Gain of methylation at maternal IC1 (H19/IGF2) 5–10% Up to 20% carry small CNVs or SNVs in the DMR; these reach 50% recurrence on the maternal allele Brioude 2018
Mosaic segmental paternal UPD of 11p15.5 20% Generally low Brioude 2018
CDKN1C pathogenic variant 5% of sporadic and 40% of familial cases 50% when inherited from the mother Brioude 2018
11p15 chromosomal abnormality <5% 50% for CNVs and balanced translocations, with parent-of-origin effects Brioude 2018
  • BWS testing. Combined IC1 gain and IC2 loss without a CNV indicates probable mosaic segmental paternal UPD. SNP-based chromosomal microarray is the most sensitive method for low-level (1–5%) mosaic upd(11)pat. A negative first-line methylation test does not exclude BWS because mosaicism can be below the limit of detection (Brioude 2018).
  • Discordant twins. Blood or saliva DNA can show IC2 loss of methylation in both affected and unaffected monozygotic twins because of shared circulation. Non-blood tissues show methylation concordant with the phenotype (Brioude 2018).
  • Silver–Russell syndrome, current and previous consensus. The second international consensus statement (2026) updates the 2016 guidelines. It restricts the diagnosis to strict molecular criteria: maternal UPD of chromosome 7 or 11p15 loss of methylation at the H19/IGF2 intergenic differentially methylated region (from an imprinting change, a CNV or maternal UPD of 11) (Wakeling 2026).

Mitochondrial disorders

  • Genome and inheritance. Mitochondrial DNA (mtDNA) is maternally inherited. Primary mitochondrial disease results from mtDNA variants or from variants in nuclear genes (Parikh 2015). More than 1400 nuclear genes contribute to mitochondrial function (Parikh 2015).
  • Heteroplasmy and threshold. Most patients with mtDNA mutations are heteroplasmic, carrying a mixture of normal and mutated mtDNA. A high mutation load is needed before a phenotype appears. In skeletal muscle the threshold is about 90% for tRNA mutations and about 70–80% for large-scale deletions (Schon 2012).
  • Germline bottleneck. In 345 individuals from 96 families, a severe germline bottleneck of 7–10 mtDNA segregating units was estimated. Divergence between mother and offspring increased with maternal age at childbirth (Zaidi 2019).
  • Population frequency. The prevalence of mtDNA-related disease is about 1 in 5000. The ten most common pathogenic mtDNA mutations together occur in about 1 in 200 people, many below the threshold for disease (Schon 2012).

Common mtDNA disorders.

Disorder Variant Heteroplasmy Inheritance Source
MELAS m.3243A>G in tRNA-Leu(UUR) (MT-TL1) Heteroplasmic Maternal Schon 2012; Parikh 2015
MERRF m.8344A>G in tRNA-Lys Heteroplasmic Maternal Schon 2012
Leber hereditary optic neuropathy m.11778G>A (MT-ND4), m.3460G>A (MT-ND1), m.14484T>C (MT-ND6) Usually homoplasmic Maternal Schon 2012
NARP and maternally inherited Leigh syndrome m.8993T>G or m.8993T>C (MT-ATP6) Lower load: NARP; higher load: Leigh Maternal Schon 2012
Kearns–Sayre syndrome, chronic progressive external ophthalmoplegia, Pearson syndrome Single large-scale deletion of about 2–10 kb Mutation load >80% in affected tissues Usually sporadic Schon 2012; Parikh 2015
mtDNA depletion and multiple deletions Nuclear genes for mtDNA maintenance Multiple deletions or reduced mtDNA copy number in affected tissue Mendelian Schon 2012; Parikh 2015
  • LHON genes. Variants in MT-ND1, MT-ND4 and MT-ND6 explain 95% of LHON (Stenton 2020).
  • Specimen choice. mtDNA sequencing and heteroplasmy analysis can be performed in blood. Urine is useful because renal epithelial cells contain abundant mtDNA, particularly for MELAS with m.3243A>G. Skeletal muscle or liver is preferred when available because of high mtDNA content and possible tissue-specific mutations absent from blood (Parikh 2015).
  • Negative blood result. A patient with a likely mtDNA disorder and a negative blood result has mtDNA tested in another tissue (Parikh 2015).
  • Methods. NGS of the whole mitochondrial genome detects point variants, low-level heteroplasmy and deletions, with heteroplasmy detection down to 5–10% and 1–2% in newer assays. Southern blot lacks sensitivity for low-level heteroplasmic deletions. Deletions and duplications may be detectable only in muscle or liver (Parikh 2015).
  • Multiple deletions. Multiple mtDNA deletions prompt sequencing of nuclear genes involved in mtDNA maintenance (Parikh 2015).
  • Nuclear genes. Comprehensive NGS panels or exome sequencing are preferred to single-gene testing because different genes produce the same phenotype (Parikh 2015). Diagnostic exome sequencing in suspected mitochondrial disease gave yields of 35%–70% across nine studies (Stenton 2020).

Hereditary hemochromatosis: HFE genotyping

Factor V Leiden and prothrombin c.*97G>A genotyping

  • Variants. Factor V Leiden is F5 c.1601G>A (p.Arg534Gln), formerly G1691A (Arg506Gln, R506Q) (Ladha 2026; Khider 2022). The prothrombin variant is F2 c.*97G>A, formerly 20210G>A, in the 3′ untranslated region (Kang 2025; Khider 2022).
  • ACMG technical standard, current and previous. The 2025 revision supersedes the standard published in 2005 and revised in 2018 (Kang 2025; Zhang 2018).
  • Indications, phenotypic assays and MTHFR. Test indications, APC resistance assays and the recommendation against MTHFR testing are taught in Thrombophilia Testing and Antiphospholipid Antibody Testing.

Spinal muscular atrophy: SMN1 and SMN2 copy number

  • Genetics. SMA affects about 1 in 10 000 live births. SMN1 and the nearly identical SMN2 lie at 5q13. Testing for homozygous absence of SMN1 exon 7 is the diagnostic test. SMN2 copy number modulates the phenotype, and carrier detection relies on accurate SMN1 copy number (Prior 2011).
  • Proportion explained by deletion. Biallelic loss of SMN1 causes about 95% of SMA (Milligan 2022).
  • SMN2 splicing. The paralogous variant c.840C>T disrupts a splice enhancer in SMN2, and only 10–20% of transcripts contain exon 7 (Milligan 2022).
  • SMN2 copy number and phenotype. SMA severity correlates inversely with SMN2 copy number, and about 90% of individuals with SMA and two SMN2 copies have SMA type 1. The SMN2 c.859G>C variant improves exon 7 inclusion; patients with two SMN2 copies and this variant typically have SMA type 2 or 3 (Milligan 2022).
  • Methods. Exon 7 copy number is measured by PCR with capillary electrophoresis, quantitative PCR, droplet digital PCR, MLPA or NGS. PCR with capillary electrophoresis quantifies only exon 7 and intron 7. MLPA quantifies all exons and detects partial deletions (Milligan 2022).
  • Silent carriers. A 2+0 genotype carries two SMN1 copies on one chromosome and none on the other. It gives the same copy number as a noncarrier (1+1). The carrier detection rate from SMN1 copy number alone ranges from about 71% to 95% by ethnicity, and most missed carriers are 2+0 (Milligan 2022).
  • Duplication markers. SMN1 c.*3+80T>G and c.*211_*212del are associated with SMN1 duplication and raise the probability of a 2+0 genotype to an extent that varies by ethnicity (Milligan 2022).
  • Other carrier genotypes. Carriers can also have a pathogenic sequence variant on one chromosome with two copies in total (1d+1) or rarer genotypes (1d+2, 3+0) (Milligan 2022).
  • Carrier frequency. SMA carrier frequency was 1/46 in people described as "Caucasian" and 1/125 in "Hispanic" individuals (Gregg 2021).
  • ACMG standard. The ACMG SMA technical standard (2011) has addenda published in 2016 and 2021 (Prior 2011; ACMG 2016; Deignan 2021).

Duchenne and Becker muscular dystrophy: DMD deletion and duplication testing

  • Gene. DMD at Xp21.2–p21.1 encodes dystrophin, which links the extracellular matrix to the cytoskeleton (Chavez-Ecos 2026).
  • Methods. Multiplex PCR detects deletions of the most commonly deleted exons in 60%–70% of patients but misses most duplications and can miss deletions in female carriers. MLPA detects deletions and duplications and misses small variants (Chavez-Ecos 2026).
  • Variant types. Deletion and duplication tests detect pathogenic variants in 65%–80% of cases and sequencing in 20%–35% (Chavez-Ecos 2026).
  • Accuracy (meta-analysis). MLPA had a sensitivity of 0.80 and specificity of 0.93. NGS had a detection rate of 0.77, rising to 0.97 when NGS followed a negative MLPA (Chavez-Ecos 2026).
  • Reading-frame rule. Out-of-frame deletions and duplications predict DMD and in-frame changes predict BMD. In 169 patients, 86.8% of DMD cases were out of frame and 70.6% of BMD cases were in frame, an overall agreement of 85.2% (Ma 2022).

Inherited cardiac and connective tissue disorders: panel testing

  • Hypertrophic cardiomyopathy. First-line panels include 8 sarcomere genes (MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3 and ACTC1) and identify a disease-causing variant in about 30% of sporadic and 60% of familial cases. Larger panels usually add little diagnostic value (Wilde 2022).
  • Long QT syndrome. Testing of the definitive genes KCNQ1, KCNH2, SCN5A, CALM1, CALM2 and CALM3 is offered to index patients with a high-probability diagnosis (Schwartz score ≥3.5) (Wilde 2022).
  • Catecholaminergic polymorphic ventricular tachycardia. The genetic testing yield is about 60% with a strong phenotype (Wilde 2022).
  • Marfan syndrome. The revised Ghent nosology makes aortic root aneurysm and ectopia lentis the cardinal features. Without a family history, both together establish the diagnosis. Without one of them, a bona fide FBN1 mutation or a combination of systemic manifestations is required. FBN1 testing is not mandatory but carries greater weight than in the earlier nosology (Loeys 2010).
  • Loeys–Dietz syndrome. Loeys–Dietz syndrome is autosomal dominant and is caused by pathogenic variants in TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2 or TGFB3 (Camerota 2019).
  • Ehlers–Danlos syndromes. The 2017 international classification recognizes 13 subtypes. The definite diagnosis of every subtype except hypermobile EDS requires identification of the causative genetic variant (Malfait 2017). Vascular EDS is autosomal dominant, is caused by COL3A1 variants and requires genetic testing for a definitive diagnosis (Bowen 2023).

Hereditary cancer syndromes: genes and testing approach

Hereditary cancer syndromes and their genes. Organ manifestations, histologic clues and organ-specific testing rules are taught in the linked units.

Syndrome Genes Inheritance Linked unit Source
BRCA1/2-associated hereditary cancer BRCA1, BRCA2 AD Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer; Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response; Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate; Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia Garutti 2023
PALB2-, CHEK2- and ATM-associated cancer PALB2, CHEK2, ATM AD (ataxia telangiectasia AR when homozygous for ATM) Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer Garutti 2023
Lynch syndrome MLH1, MSH2, MSH6, PMS2, EPCAM AD Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing; Endometrial Carcinoma: Histologic Types and Molecular Classification Garutti 2023
Familial adenomatous polyposis and attenuated FAP APC AD Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing Garutti 2023
MUTYH-associated polyposis MUTYH AR Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing Garutti 2023
Peutz–Jeghers syndrome STK11 AD Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing Garutti 2023; Syngal 2015
Cowden syndrome PTEN AD Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing Garutti 2023; Syngal 2015
Hereditary diffuse gastric cancer CDH1 AD Gastric Dysplasia, Gastric Carcinoma, Gastroesophageal Biomarkers and Small Intestinal Adenocarcinoma Garutti 2023; Syngal 2015
Li–Fraumeni syndrome TP53 AD Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing Garutti 2023
Von Hippel–Lindau syndrome VHL AD Renal Cell Carcinoma and Oncocytic Renal Tumors; Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms Garutti 2023
Multiple endocrine neoplasia type 1 MEN1 AD Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms Garutti 2023
Multiple endocrine neoplasia type 2A and 2B; familial medullary thyroid carcinoma RET AD High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging Garutti 2023
Hereditary paraganglioma–pheochromocytoma SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX, TMEM127 AD; SDHD, SDHAF2 and MAX show paternal-transmission effects Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms Garutti 2023
  • Sequencing with dosage analysis. CDH1 testing includes sequencing and deletion/duplication analysis; 4% of CDH1 mutations are large rearrangements (Syngal 2015). Up to a third of STK11 mutations in Peutz–Jeghers syndrome are large deletions (Syngal 2015). Whole-exon deletions and duplications form a substantial proportion of BRCA1 and MSH2 pathogenic variants (Mandelker 2019).
  • Cascade testing. Cascade testing tests at-risk relatives for the familial pathogenic variant. Reported uptake is typically below 30% (Chiang 2024).

MLH1 promoter methylation assays and constitutional MLH1 epimutation

  • MLH1 promoter methylation assays. Tumor methylation is measured by locus-specific methods such as MethyLight and methylation-sensitive high-resolution melting; one study called tumors positive above 10% methylation by MethyLight and above 5% by MS-HRM (Joo 2023).
  • Constitutional MLH1 epimutation. Monoallelic soma-wide MLH1 promoter methylation arises de novo (primary epimutation) or from a cis-acting genetic variant (secondary epimutation), and the type determines transmissibility. Mosaic constitutional methylation at low levels is unlikely to be detected by MS-MLPA and is detected by methylation-sensitive droplet digital PCR (Joo 2023).

Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing

Definition. Solid-tumor molecular testing identifies somatic alterations that establish a diagnosis, predict response to a targeted drug or immunotherapy, or indicate a germline cancer predisposition. ESMO recommends tumor NGS in advanced non-squamous non-small cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma and ovarian cancer. The 2024 update extends the recommendation to advanced breast cancer, gastrointestinal stromal tumors, sarcoma, thyroid cancer and cancer of unknown primary, and to tumor-agnostic alterations when matched therapy is available (Mosele 2024).

Related page: Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation (NGS chemistry, RNA fusion assays, ctDNA, validation, HGVS, companion diagnostics) Related page: Variant Classification, Inheritance and Genomic Testing: Inheritance Patterns, Hardy–Weinberg and Bayesian Risk, ACMG/AMP Germline Classification with ClinGen Refinements, AMP/ASCO/CAP Somatic Tiers, Oncogenicity, Secondary Findings, Consent, Exome and Genome Sequencing and Carrier Screening (AMP/ASCO/CAP somatic tiers and ClinGen/CGC/VICC oncogenicity) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (break-apart and dual-fusion FISH probes) Related page: Molecular Testing for Inherited Disease: Cystic Fibrosis, Fragile X and Other Repeat Expansions, Imprinting and Mitochondrial Disorders, Hemochromatosis, Thrombophilia, Neuromuscular and Cardiac Disorders, Hereditary Cancer Syndromes and Lynch Syndrome (hereditary cancer syndromes and Lynch syndrome laboratory testing) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (MMR immunohistochemistry interpretation, MLH1 promoter methylation and BRAF V600E triage) Related page: Molecular Testing and Predictive Biomarkers on Cytology Specimens (cytology specimens for NGS, cell blocks, smears and supernatant cell-free DNA) Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (clonal hematopoiesis variants as a source of false-positive ctDNA and tumor calls)

Oncogenes, tumor suppressor genes and driver mutations

  • Two-hit model. In dominantly inherited retinoblastoma one mutation is inherited through the germ cells and the second occurs in somatic cells. In the nonhereditary form both mutations are somatic (Knudson 1971).
  • Driver and passenger mutations. A driver mutation confers a selective growth advantage, and a passenger mutation has no effect on growth. A typical tumor contains two to eight driver gene mutations (Vogelstein 2013). About 140 genes promote tumorigenesis when altered by intragenic mutations (Vogelstein 2013).
  • Mutation pattern. Oncogenes are recurrently mutated at the same amino acid positions. Tumor suppressor genes carry protein-truncating alterations throughout their length (Vogelstein 2013).
  • 20/20 rule. A gene is classified as an oncogene when >20% of its recorded mutations are recurrent missense mutations, and as a tumor suppressor gene when >20% are inactivating (Vogelstein 2013).
  • Driver gene versus driver mutation. A driver gene can also carry passenger mutations. In APC, only mutations that truncate the protein within its N-terminal 1600 amino acids are drivers (Vogelstein 2013).
  • Clonal evolution. Heterogeneity between tumor regions is largely confined to passenger mutations. Driver genes are usually present in the trunk of the phylogenetic tree (Vogelstein 2013).

Mechanisms of gene activation or inactivation and the assay that detects each.

Mechanism Example Assay Source
Point mutation in an oncogene hotspot EGFR, BRAF V600E, KRAS Targeted PCR or NGS; EGFR mutation testing by immunohistochemistry is not recommended Lindeman 2018; Vogelstein 2013
Gene amplification ERBB2 in breast and gastroesophageal adenocarcinoma Immunohistochemistry with in situ hybridization Wolff 2023; Bartley 2016
Gene fusion ALK, ROS1, RET, NTRK1–3 FISH, immunohistochemistry (ALK, ROS1, pan-TRK), RT-PCR, DNA or RNA NGS Lindeman 2018; Marchiò 2019
Inactivating mutation and loss of the second allele TP53, APC, RB1 NGS with copy-number and allele-fraction analysis Knudson 1971; Vogelstein 2013
Homozygous deletion CDKN2A/B in IDH-mutant astrocytoma Copy-number analysis by NGS, array or FISH Louis 2021; Vogelstein 2013
Protein overexpression without a DNA change HER2 IHC 3+ as a tumor-agnostic marker Immunohistochemistry Kim 2025

Microsatellite instability and mismatch repair deficiency as assays

  • Definitions. MSI is the form of genomic instability caused by defective DNA mismatch repair (MMR). With the five-marker reference panel, instability at two or more markers is MSI-high and at one marker MSI-low. Normal tissue is required to document MSI (Boland 1998).
  • PCR panels. The NCI panel contains two mononucleotide markers (BAT-25, BAT-26) and three dinucleotide markers (D2S123, D5S346, D17S250). The pentaplex panel contains five mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24, NR-27) (Chung 2023). Tumor and normal DNA are amplified, and allele lengths are compared by capillary electrophoresis (Chung 2023).
  • MSI by NGS and TMB. The CAP guideline evaluated MMR immunohistochemistry, MSI by PCR, MSI by NGS and TMB from large-panel NGS (Bartley 2022).
  • MMR immunohistochemistry. Loss of nuclear MLH1, MSH2, MSH6 or PMS2 expression identifies MMR deficiency (Chung 2023). Interpretation patterns and pitfalls are taught in Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing.

CAP 2022 guideline on MMR and MSI testing for immune checkpoint inhibitor therapy (ASCO-endorsed).

Tumor type Recommended assays Source
Colorectal cancer MMR immunohistochemistry, MSI by PCR or MSI by NGS Vikas 2023
Gastroesophageal and small bowel cancer MMR immunohistochemistry or MSI by PCR Vikas 2023
Endometrial cancer MMR immunohistochemistry only Vikas 2023
Other cancers No method recommended over another; immunohistochemistry is acceptable and available in most laboratories Bartley 2022; Vikas 2023
TMB Not recommended as a surrogate for MMR deficiency Vikas 2023
  • First tumor-agnostic approval. Pembrolizumab was approved on May 23, 2017, for unresectable or metastatic MSI-high or dMMR solid tumors that progressed after prior treatment. The overall response rate was 39.6% among 149 patients with 15 tumor types, and 78% of responses lasted ≥6 months. It was the first FDA cancer approval based on a common biomarker independent of the primary site (Marcus 2019).

Tumor mutational burden

  • Definition. TMB is the number of somatic mutations per megabase of interrogated genomic sequence. Whole-exome sequencing is the optimal method, and targeted panels give TMB estimates (Merino 2020).
  • Sources of variability. Panel size, gene coverage and bioinformatics pipelines cause variability between laboratories. Variability within and between panel TMB values increases as the true TMB increases (Merino 2020).
  • Harmonization. All laboratories in the harmonization study counted exonic somatic nonsynonymous, frameshift and splice-site variants and short indels; 8 of 11 panels also counted synonymous variants. Panel TMB is aligned to an external reference standard during analytical validation, and TMB is reported in mut/Mb (Merino 2020).
  • Panel size. Panels covering about 1 megabase or more are recommended as the lower limit for reliable TMB estimation (Stenzinger 2019).
  • TMB-high approval. Pembrolizumab received accelerated approval on June 16, 2020, for TMB-high solid tumors (≥10 mut/Mb) determined by an FDA-approved test. The overall response rate was 29% in 102 patients with nine tumor types in KEYNOTE-158 (Marcus 2021). FoundationOne CDx was approved as the companion diagnostic at a cut point of 10 mut/Mb. A whole-exome TMB of ≥175 mutations per exome is approximately equivalent to ≥10 mut/Mb by that assay (Marcus 2021).
  • Hypermutated tumors. POLE-ultramutated endometrial carcinomas have a markedly increased transversion mutation frequency (TCGA 2013). The four TCGA genomic classes are taught in Endometrial Carcinoma: Histologic Types and Molecular Classification.

Tumor-agnostic biomarkers and assay choice

FDA tissue-agnostic approvals.

Biomarker Drug and approval date Assay choice Source
MSI-high or dMMR Pembrolizumab, May 2017; dostarlimab (dMMR), August 2021 MMR IHC, MSI-PCR or MSI-NGS by tumor type (CAP 2022) Marcus 2019; Kim 2025; Vikas 2023
TMB-high (≥10 mut/Mb) Pembrolizumab, June 2020 FDA-approved NGS panel Marcus 2021
NTRK1/2/3 fusion Larotrectinib, November 2018; entrectinib, August 2019; repotrectinib, June 2024 RNA sequencing or pan-TRK IHC screening followed by sequencing Kim 2025; Marchiò 2019
BRAF V600E Dabrafenib with trametinib, June 2022 PCR, NGS or BRAF V600E (VE1) IHC Kim 2025; Lo 2016
RET fusion Selpercatinib, September 2022 DNA or RNA NGS, FISH Kim 2025; Lindeman 2018
HER2 IHC 3+ Trastuzumab deruxtecan, April 2024 Immunohistochemistry Kim 2025

NTRK fusion detection.

  • Frequency. NTRK fusions occur in <1% of solid tumors overall and in >90% of mammary analogue secretory carcinoma and infantile fibrosarcoma. Among common tumors they occur in 1%–6% of adult and 4%–26% of pediatric papillary thyroid carcinomas (Marczyk 2025), 0.7%–1.5% of colorectal cancers and 0.2%–0.3% of lung cancers (Kim 2025).
  • ESMO strategy. Where NTRK fusions are highly recurrent, FISH, RT-PCR or RNA-based panels confirm the fusion. In unselected populations, testing uses front-line sequencing, preferably RNA sequencing, or immunohistochemistry screening followed by sequencing of positive cases (Marchiò 2019).
  • DNA-based NGS. DNA-based NGS misses NTRK fusions whose breakpoints are outside the covered regions; its sensitivity against RNA sequencing is given in Molecular and Ancillary Testing of Soft Tissue FNA Material (Solomon 2020).
  • Pan-TRK immunohistochemistry. Overall sensitivity was 87.9% and specificity 81.1%. Sensitivity was 96% for NTRK1, 100% for NTRK2 and 79% for NTRK3 fusions. Specificity was 100% in colon, lung, thyroid, pancreas and biliary carcinomas, 82% in breast and 52% in salivary carcinomas, and staining occurred in tumors with neural differentiation. Sensitivity and specificity were poor in sarcomas (Solomon 2020).

Cross-organ biomarker summary

The organ-specific testing rules, cutoffs and reporting templates are taught in the linked units.

Organ Key alterations Preferred assay type Owning unit Source
Lung (adenocarcinoma) EGFR, ALK, ROS1; ERBB2, MET, BRAF, KRAS and RET on NGS panels NGS panel; ALK and ROS1 IHC as alternatives to FISH; cell-free DNA to rule in a mutation when tissue is limited Lung Cancer Predictive Biomarkers: Driver Genes, PD-L1 Immunohistochemistry and Specimen Handling Lindeman 2018
Colorectal MMR or MSI, KRAS, NRAS, BRAF V600E MMR IHC or MSI-PCR; mutation panel Colorectal Cancer Staging, CAP Reporting, Biomarkers and Neoadjuvant Response Sepulveda 2017; Vikas 2023
Breast HER2 protein and ERBB2 amplification; HER2-low for trastuzumab deruxtecan IHC with ISH Breast Cancer Biomarkers: ER, PR, HER2, Ki-67 and Multigene Assays Wolff 2023
Melanoma BRAF V600 PCR, NGS or VE1 IHC Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma Lo 2016
GIST KIT; PDGFRA in about 35% of KIT-wild-type tumors Mutation analysis by sequencing Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine Heinrich 2003
Thyroid BRAF, RAS, kinase fusions; germline or somatic RET in medullary carcinoma NGS panel; RET germline testing Thyroid Molecular Testing; High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging TCGA 2014; Wells 2015
Sarcoma Fusion genes and amplifications RNA NGS, break-apart FISH, IHC surrogates Molecular and Ancillary Testing of Soft Tissue FNA Material Cloutier 2025; Solomon 2020
Endometrium POLE, MMR deficiency, TP53 MMR IHC, POLE sequencing, p53 IHC Endometrial Carcinoma: Histologic Types and Molecular Classification TCGA 2013; Vikas 2023
Ovary Germline and somatic BRCA1/2 Germline panel, then tumor BRCA1/2 if germline negative Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response Konstantinopoulos 2020
Prostate Germline DNA-repair genes (BRCA2 5.3%, ATM, CHEK2, BRCA1) Germline panel; tumor NGS Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate Pritchard 2016
Gastroesophageal HER2; MMR HER2 IHC with ISH; MMR IHC or MSI-PCR Gastric Dysplasia, Gastric Carcinoma, Gastroesophageal Biomarkers and Small Intestinal Adenocarcinoma Bartley 2016; Vikas 2023
Pancreas KRAS, TP53, CDKN2A, SMAD4; other drivers in KRAS-wild-type tumors NGS panel Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia TCGA 2017
Bladder FGFR3 alterations FDA-approved companion diagnostic Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder Maguire 2026
Kidney VHL (frequent somatic in renal cancer); TFE3 rearrangement Sequencing; cathepsin K and TFE3 IHC Renal Cell Carcinoma and Oncocytic Renal Tumors Mandelker 2019; Kim 2020

Melanoma BRAF testing methods

EWSR1 break-apart FISH limits

  • Partner not identified. Break-apart FISH does not identify the fusion partner (Cusenza 2021).
  • EWSR1::PATZ1. FISH is not used to confirm EWSR1::PATZ1 because the two genes are close together on 22q12; NGS or RT-PCR is used (Flucke 2021).
  • Range of tumors. EWSR1 rearrangements occur in diverse benign and malignant tumors with mesenchymal, neuroectodermal and epithelial or myoepithelial features (Flucke 2021). Sarcoma fusions by entity and CIC and pan-TRK assay performance are taught in Molecular and Ancillary Testing of Soft Tissue FNA Material.

CNS tumor molecular testing

WHO CNS5 principles (2021).

  • Integrated diagnosis. WHO CNS5 emphasizes integrated diagnoses and layered reports. A layered report places the integrated diagnosis at the top, followed by histologic, molecular and other layers (Louis 2021).
  • Grading. CNS WHO grade is no longer restricted to histology. CDKN2A/B homozygous deletion makes an IDH-mutant astrocytoma CNS WHO grade 4 even without microvascular proliferation or necrosis (Louis 2021).
  • Adult diffuse gliomas. WHO CNS5 recognizes three types: astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype (Louis 2021). The 2016 classification divided the common adult diffuse gliomas into 15 entities (Louis 2021).
  • Glioblastoma, IDH-wildtype. The diagnosis is made in an adult IDH-wildtype diffuse astrocytic glioma with microvascular proliferation, necrosis, TERT promoter mutation, EGFR amplification or combined gain of chromosome 7 and loss of chromosome 10 (+7/−10) (Louis 2021).
  • cIMPACT-NOW update 11 (2026). Caution is advised in assigning grade 4 to a histologically low-grade IDH-wildtype tumor with a TERT promoter mutation only. EGFR amplification and +7/−10 are not used as solitary defining features of glioblastoma in patients younger than 40 years, and diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, is considered in adults, especially those younger than 40 years (Wesseling 2026). PDGFRA alteration, EGFR alteration or MYCN amplification count as key features of diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, only in patients younger than 25 years (Wesseling 2026).
  • Diffuse midline glioma. The name changed from "H3 K27M-mutant" (2016) to "H3 K27-altered" (WHO CNS5) to include other mechanisms such as EZHIP overexpression (Louis 2021).
  • NOS and NEC. NOS indicates that the information needed for a WHO diagnosis is unavailable, for example molecular testing not done or failed. NEC indicates that testing was performed but the results do not fit a WHO diagnosis (Louis 2021).

Glioma biomarker testing methods (EANO 2021).

Biomarker Method Rule Source
IDH1 R132H and ATRX Immunohistochemistry Performed routinely in diffuse gliomas Weller 2021
Non-canonical IDH1 and IDH2 Sequencing of IDH1 codon 132 and IDH2 codon 172 When R132H IHC is negative in WHO grade 2 and 3 gliomas and in glioblastomas of patients <55 years Weller 2021
IDH-wildtype status by IHC alone IDH1 R132H immunohistochemistry Sufficient in patients >55 years with histologically typical glioblastoma, no prior lower-grade glioma, non-midline location and retained ATRX Weller 2021
1p/19q codeletion Codeletion analysis Determined in IDH-mutant gliomas with retained nuclear ATRX; ATRX loss establishes astrocytic lineage without 1p/19q testing Weller 2021
MGMT promoter methylation Methylation-specific PCR, pyrosequencing or methylation arrays (MGMT-STP27 model); immunohistochemistry is not adequate Determined in glioblastoma, notably in elderly or frail patients, to guide temozolomide Weller 2021
H3.3 G34R/V Immunohistochemistry or sequencing Assessed in young patients with IDH-wildtype gliomas, such as those <50 years with ATRX loss Weller 2021
  • Sampling. IDH mutation, 1p/19q codeletion and MGMT promoter methylation are homogeneous within tumors, so the risk of sampling error is low (Weller 2021).
  • DNA methylation profiling. Methylome profiling is an effective ancillary method for CNS tumor classification alongside histology. It can identify some rare tumor types and serve as a surrogate for genetic events, but it does not replace demonstration of a specific mutation when targeted therapy requires one (Louis 2021).
  • Classifier scores. Calibrated score thresholds are set at 0.84 or 0.90. Diagnoses suggested with scores below 0.84 are treated with caution, and those below 0.50 are discarded. Low tumor cell content limits classification, for example in low-grade diffuse gliomas (Louis 2021).

1p/19q codeletion methods.

  • Lesion. The oligodendroglioma codeletion is whole-arm loss of 1p and 19q from an unbalanced t(1;19)(q10;p10) (Ball 2020).
  • FISH. FISH probes at 1p36 and 19q13 cover only about 0.4%–1.5% of each arm, so FISH cannot distinguish partial from whole-arm codeletion. Partial codeletion gave a false-positive FISH result in 3.6% of adult diffuse astrocytic gliomas (8 of 223): 4.6% of IDH-mutant and 2.9% of IDH-wildtype tumors (Ball 2020).
  • Copy-number methods. Chromosomal microarray, array CGH, DNA methylation arrays and NGS distinguish partial from whole-arm codeletion (Ball 2020).
  • Other methods. PCR-based loss-of-heterozygosity analysis needs heterozygous microsatellites and DNA from normal tissue, and G banding is not suitable for 1p/19q analysis (Brandner 2022).

MGMT promoter methylation methods.

  • Comparison. Methylation-specific PCR and pyrosequencing were more prognostic than immunohistochemistry in temozolomide-treated glioblastoma (Brandner 2021).
  • CpG sites. Methylation-specific PCR has been studied mainly at CpG sites 76–80 and 84–87, and pyrosequencing at CpG sites 72–95 (Brandner 2021).
  • Cutoffs. A 9% pyrosequencing cutoff at CpG sites 74–78 performed better than 28% or 29% cutoffs in 2 of 3 good-quality studies (Brandner 2021).
  • Array model. MGMT-STP27 is a logistic regression model built on two Infinium array probes, cg12434587 and cg12981137 (Bady 2012).

Germline findings on tumor sequencing

  • Why tumor-only results suggest germline variants. A heterozygous germline variant is present in about 50% of alleles in every tissue, including tumor. Somatic variants usually have VAF <50% because of clonal heterogeneity, admixed non-tumor cells and aneuploidy, but loss of heterozygosity can raise a somatic VAF above 50% (Mandelker 2019).
  • Germline conversion rate. The ESMO Precision Medicine Working Group defined the germline conversion rate as the percentage of tumor-detected pathogenic variants that are germline. In 16 322 paired tumors, VAF filtering and gene-context-age criteria reduced the variants needing germline follow-up by 94%, to 6.4% of tumors, and 62.7% of the remaining variants were germline (Mandelker 2019).

ESMO recommendations for germline-focused analysis of tumor-only sequencing (2019).

Item Recommendation Source
Scope Performed routinely on large tumor panels by an automated pipeline Mandelker 2019
Variants flagged Truncating variants in loss-of-function genes and variants classified pathogenic or likely pathogenic in a curated resource (ClinVar) Mandelker 2019
VAF filter VAF >30% for SNVs and >20% for small insertions and deletions, with local validation of VAF accuracy Mandelker 2019
Genes followed up in any tumor type at any age BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, VHL (renal tumors excluded), RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TSC2, and MUTYH when biallelic Mandelker 2019
Genes followed up in the associated tumor type only FLCN, FH, BAP1, POLE Mandelker 2019
Genes followed up only in tumors arising before age 30 years RB1 and APC (any tumor); TP53 and NF1 (associated tumor) Mandelker 2019
Negative tumor result Not equivalent to a negative germline result unless dosage analysis is reliable, particularly for BRCA1 and MSH2 Mandelker 2019
Confirmation The variant is tested in a germline sample (blood lymphocytes, saliva or buccal swab, normal tissue) in a laboratory accredited for germline testing, after information and consent Mandelker 2019
  • Somatic background genes. Only 1% of 2930 tumor-detected TP53 pathogenic variants were germline. Only 0.3% of APC variants in colorectal cancers were germline, and 6% of VHL variants in renal tumors were germline (Mandelker 2019).

Molecular Testing in Hematolymphoid Neoplasms: NGS Panels, FLT3 and BCR::ABL1 Assays, IG and TR Clonality and Molecular Measurable Residual Disease

Definition. Molecular testing in hematolymphoid neoplasms detects gene mutations, fusion transcripts and antigen receptor gene rearrangements for diagnosis, risk assignment, therapy selection and measurable residual disease (MRD).

Related page: Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition (myeloid workup, CHIP and CCUS, VAF thresholds, germline predisposition genes, AML MRD with ELN-DAVID 2025) Related page: Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk (FLT3 and NPM1 clinical meaning, ELN 2022 risk) Related page: Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms (BCR::ABL1 transcript types, International Scale response levels, ELN 2025 milestones, kinase domain mutations) Related page: B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease (B-ALL genetic subtypes, BCR::ABL1-like ALL, MRD) Related page: Classification of Lymphoid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry and Immunohistochemistry in Hematopathology (flow cytometric clonality and TRBC1) Related page: Mature T-Cell and NK-Cell Neoplasms: Nodal, Leukemic, Extranodal and Cutaneous T-Cell Lymphomas (TCR PCR in T-cell neoplasms) Related page: Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation (NGS chemistry, UMIs, bioinformatics and validation) Related page: Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA (RT-qPCR, digital PCR and capillary fragment analysis)

Myeloid and lymphoid NGS panels

Method comparison for hematologic neoplasms (Duncavage 2022).

Method Breadth Typical depth or sensitivity Main use Source
FISH Targeted regions Abnormalities in 1%–5% of cells (about 10⁻²); turnaround 1–3 days Cryptic rearrangements, copy-number changes Duncavage 2022
Sanger sequencing Single exons (CEBPA, CALR) About 20% VAF Rapid single-gene testing Duncavage 2022
Targeted NGS panel 50–500 genes About 1000× coverage; about 2% VAF Initial diagnostic evaluation Duncavage 2022
Whole-genome sequencing Whole genome, including structural variants and copy-number changes About 60× coverage; VAF >10% Comprehensive profiling Duncavage 2022
MRD sequencing panel Selected targets Higher depth with UMIs; about 0.1% VAF MRD monitoring Duncavage 2022
  • Enrichment. Targets are enriched by hybrid capture with DNA or RNA probes or by PCR amplification (amplicon enrichment) (Duncavage 2022).
  • VAF. VAF is the number of reads containing a variant divided by the total reads at that position. It is semiquantitative and differs slightly between laboratories (Duncavage 2022).
  • Clone size. Most somatic mutations are heterozygous, so doubling the VAF estimates the fraction of cells carrying the mutation, except in regions of copy-number alteration. Aneuploidy, loss of heterozygosity and amplification or deletion skew VAFs (Duncavage 2022).
  • Germline variants. Many laboratories infer variants near 50% VAF outside copy-number-altered regions as germline and filter known polymorphisms with population databases. A VAF of 30%–60% on an appropriate sample suggests a germline variant (Duncavage 2022).
  • Indications for germline testing. Indications are taught in Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.
  • Error correction. Error-corrected deep sequencing tags each DNA molecule with a unique molecular identifier and reduces false-positive calls at low VAF (Duncavage 2022).
  • Fusion detection in B-ALL. Capture-based and amplicon-based assays detect most common fusions in B-ALL. They can miss complex rearrangements such as EPOR rearrangements in BCR::ABL1-like B-ALL and fusions with intronic breakpoints (Duncavage 2022).

FLT3 testing methods

  • Separate assays and the allelic ratio. Separate PCR and capillary electrophoresis testing of FLT3-ITD and FLT3-TKD and the allelic ratio definition are taught in Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk.
  • DNA versus cDNA. In 259 adults with FLT3-ITD AML, DNA and cDNA AR correlated (Spearman R 0.86). cDNA ARs were often higher, cDNA detected FLT3-ITD in 11 patients (4.2%) missed on DNA, and ITD lengths were identical. The data support genomic DNA-based AR measurement as the standard (Cucchi 2021).
  • ITD length. ITD lengths over 90 bp at the DNA level occurred because of intron splicing. A length of ≥48 bp predicted poor overall survival in one cohort but not in another (Cucchi 2021).
  • Midostaurin threshold. The RATIFY trial used an AR of 0.05 for eligibility (Cucchi 2021).

Multiplex FLT3 fragment analysis (Murphy 2003).

  • Design. FLT3-ITD and D835 mutations are detected in one multiplex PCR with fluorescent primers, EcoRV digestion and capillary electrophoresis.
  • ITD. Duplicated segments range from 6 to 180 bases and are always in frame. The wild-type juxtamembrane product is 330 bases, and ITD products are longer.
  • D835. EcoRV digestion cuts the wild-type D835 product to 80 bases. A D835 mutation destroys the site, and the mutant product sizes at 129 bases.
  • Sensitivity. The assay detects 10% heterozygous malignant cells (5% of alleles). Fragment analysis has low priority for MRD because of limited sensitivity (Schuurhuis 2018).

The clinical meaning of FLT3 and NPM1 results is taught in Acute Myeloid Leukemia with Defining Genetic Abnormalities, Acute Promyelocytic Leukemia and ELN 2022 Genetic Risk.

NPM1, IDH1/IDH2 and KIT D816V assays

  • NPM1 mutation types. Most NPM1 mutations are 4-base insertions causing a frameshift. Type A (TCTG) accounts for about 80%, and types B (CATG) and D (CCTG) for about 10% (Pastore 2014). More than 50 mutations in exon 11 have been described (Lesieur 2021).
  • NPM1 MRD. RT-qPCR monitoring is mostly limited to types A, B and D, for which commercial plasmid standards exist; other types need patient-specific or digital PCR assays. Failure to reach a 4-log reduction of NPM1 transcripts in peripheral blood predicts a higher cumulative incidence of relapse (Lesieur 2021).
  • IDH1 and IDH2. IDH1 R132 and IDH2 R140 and R172 are detected by NGS, which was limited to a VAF of 3% in one study; mutation-specific droplet digital PCR detects them at MRD levels (Bill 2023).
  • Single-marker MRD. ELN advises against FLT3-ITD, FLT3-TKD, NRAS, KRAS, DNMT3A, ASXL1, IDH1, IDH2 and MLL-PTD as single MRD markers (Schuurhuis 2018).
  • KIT D816V. Sanger sequencing of KIT has a sensitivity of only 10%–20%. Allele-specific qPCR detects fewer than 0.01% D816V-positive cells; other codon 816 variants are detected by RFLP or HPLC methods and not by allele-specific qPCR. PNA-mediated PCR clamping is the recommended method for FFPE marrow trephines (Arock 2015).

Myeloproliferative neoplasm driver assays

Target Assay facts Source
JAK2 V617F Allele-specific qPCR limit of detection 0.12%; droplet digital PCR lower Link-Lenczowska 2018
JAK2 V617F at low burden Allele burdens of 1%–3% are not detectable by Sanger sequencing or pyrosequencing Jovanovic 2013
CALR exon 9 Type 1 (52-bp deletion) and type 2 (5-bp insertion) make up 85% of mutations; all are insertions or deletions, and fragment analysis is the most practical detection method Prins 2020
MPL Most common mutations are W515L and W515K Mroczkowska-Bękarciak 2023

BCR::ABL1 testing and the International Scale

Assay design (2006 harmonization recommendations).

  • Transcript identification at diagnosis. RT-qPCR at diagnosis identifies the common e13a2 (b2a2) or e14a2 (b3a2) transcripts or a less common transcript that standard primer sets do not amplify. This prevents a falsely undetectable result during therapy (Hughes 2006). Transcript types and their clinical associations are taught in Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms.
  • Atypical transcripts. e1a2 encodes p190 and e19a2 encodes p230 BCR::ABL1. About 2% of CML expresses atypical fusions with breakpoints outside M-BCR or downstream of ABL1 exon 2. Screening only for p210, or p210 plus p190, may misdiagnose up to 2% of CML. These patients are monitored with bespoke RT-qPCR or RT-dPCR assays, and their results cannot be expressed on the IS (Cross 2023).
  • Specimen. Peripheral blood is suitable for monitoring chronic-phase CML (Hughes 2006).
  • Control gene. ABL1, BCR and GUSB are suitable control genes. ABL1 is the most widely used. BCR degrades at the same rate as BCR::ABL1, and GUSB has the advantage that it is not rearranged in the leukemic clone (Hughes 2006).
  • Assay chemistry. Hydrolysis and hybridization probe technologies give comparable results when standardized procedures are followed. Assay design accounts for the polymorphic site in BCR exon 13 and for amplification of genomic DNA across the small intron between ABL1 exons 2 and 3 (Hughes 2006).
  • Contamination control. PCR products, undiluted BCR::ABL1 and control plasmids are never introduced into the sample preparation area (Hughes 2006).
  • Limit of detection. The cutoff is usually the lowest plasmid dilution amplified reliably, about 5–10 molecules. Sensitivity depends on cell number, control gene transcripts and PCR performance and is calculated for each sample, so an undetectable result is reported with its sample sensitivity (Hughes 2006).

International Scale (IS).

  • Anchors. The standardized baseline from the IRIS trial is 100% on the IS, and major molecular response (MMR), a 3-log reduction from that baseline, is fixed at 0.10% (Hughes 2006).
  • Conversion factor. Each laboratory determines the local BCR::ABL1/control ratio equivalent to MMR (MMREq) by exchanging samples or using reference material. The conversion factor (CF) is 0.1% divided by MMREq, and the IS value is the local value multiplied by the CF (Hughes 2006).
  • Validity of the CF. The CF is laboratory-specific and changes with technical changes to the assay. With ABL1 as the control gene, conversion at high transcript levels is less satisfactory because the ratios are nonlinear (Hughes 2006).

International Scale conversion examples.

Laboratory MMREq (local %) Conversion factor Conversion of a local result Source
Adelaide 0.08 0.1 ÷ 0.08 = 1.25 Local value × 1.25 Hughes 2006
Mannheim 0.12 0.1 ÷ 0.12 = 0.83 Local value × 0.83 Hughes 2006

Scoring deep molecular response (Cross 2015). MR4, MR4.5 and MR5 and the minimum ABL1 and GUSB control counts are tabulated in Myeloproliferative Neoplasms: Chronic Myeloid Leukemia with Molecular Monitoring, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis and Other Myeloproliferative Neoplasms.

IG and TR clonality testing

  • Principle. The diversity of IG and TR molecules is about 10¹². Identical rearrangements therefore reflect a clonal population, and clonality testing evaluates whether rearrangements are homogeneous or heterogeneous (Langerak 2012). PCR has replaced Southern blot as the standard method (Langerak 2012).
  • BIOMED-2 primers. The BIOMED-2 multiplex assays use 107 primers in 18 tubes: three IGH VH–JH, two IGH DH–JH, two IGK, one IGL, three TRB, two TRG and one TRD tube, plus tubes for t(11;14) and t(14;18). Products are analyzed by heteroduplex analysis or GeneScan fragment analysis (van Dongen 2003).
  • Complementary targets. IGH (VH–JH and DH–JH) with IGK detects virtually all clonal B-cell proliferations, including those with heavy somatic hypermutation. TRB with TRG detects virtually all clonal T-cell populations, and TRD adds value in TRγδ proliferations (van Dongen 2003). IGH VH–JH with IGK suffices in more than 95% of B-cell cases (Langerak 2012).
  • Qualitative assay. Multiplex clonality PCR uses primers of different efficiencies, so it is qualitative and interpretation is based on pattern recognition (Langerak 2012).
  • Two clonal peaks. Two clonal peaks more often reflect biallelic rearrangement than biclonality. True biclonality occurs in up to 5% of mature B-cell lymphoproliferative disorders (Langerak 2012).

Pre-analytical and analytical requirements (EuroClonality/BIOMED-2, 2012).

Step Requirement Source
Specimen Assays are standardized for fresh or frozen material; FFPE DNA is tested at two or more concentrations because of PCR inhibition Langerak 2012
DNA quality BIOMED-2 control gene multiplex PCR; amplification of 300-nt fragments predicts reliable results, and smaller targets may be evaluable at 200 nt Langerak 2012
Replicates Every target in duplicate (independent amplifications); with limited DNA, duplicate testing of one tube is preferred over testing more targets Langerak 2012
Clinical data Prior anti-CD20 therapy and FISH results are recorded Langerak 2012

Sources of error in IG and TR clonality interpretation.

Finding Cause Solution Source
No clonal or polyclonal product Poor DNA quality; few lymphocytes; anti-CD20 therapy (B cells) Control gene PCR; more DNA per reaction Langerak 2012
False-negative B-cell result Somatic hypermutation blocks primer annealing; t(11;14) or t(14;18) Targets less prone to hypermutation (IGH DH–JH, IGK Kde) Langerak 2012
Pseudoclonality Few B or T cells (for example in skin) cause preferential amplification; peaks differ in size between duplicates Duplicate PCR; increase template Langerak 2012
Multiple reproducible peaks Exaggerated immune response in infection or inflammation (oligoclonality) Interpret with histology Langerak 2012
Up to four IGK or TRB products Compatible with a single clone Knowledge of locus structure Langerak 2012
Clonal IG in a T-cell tumor or the reverse Cross-lineage rearrangement, frequent in immature lymphoid malignancies Clonal results not used alone for lineage assignment Langerak 2012

EuroClonality molecular conclusions. The system was difficult to apply in only 36 of 1150 routine cases (about 3.1%) (Langerak 2012).

Molecular conclusion Profile Source
Clonality detected One or two reproducible peaks or bands, with or without a polyclonal background; not every target has to be clonal Langerak 2012
Oligoclonality or multiple clones detected Several reproducible peaks Langerak 2012
Clonality detected, with a polyclonal background (optional conclusion) One or two clear peaks on a Gaussian background Langerak 2012
Irregular polyclonal (technical description) Largely polyclonal profile with some minor peaks Langerak 2012
Polyclonality detected Gaussian GeneScan curve or heteroduplex smear Langerak 2012
No clonality detected, suggestive of low template amount Pseudoclonal or non-reproducible products Langerak 2012
No rearrangements in IG/TR targets detected No specific products in any target Langerak 2012
Not evaluable Poor DNA quality or unevaluable profiles Langerak 2012

NGS-based clonality.

  • EuroClonality-NGS validation. In 209 reactive and neoplastic specimens, NGS-based IG clonality had 99% interlaboratory concordance and 98% concordance with conventional BIOMED-2 analysis for the molecular conclusion. A clone was detected in 96% of B-cell neoplasms by NGS and 95% by conventional analysis (van den Brand 2021).
  • Small amplicons. The EuroClonality-NGS assay generates small amplicons suited to FFPE DNA (van den Brand 2023).
  • DEPART algorithm. NGS clonality results are assessed in order: sample quality, pattern of clonotypes, abundance of the dominant clonotypes and ratio between the dominant clonotypes and the background (van den Brand 2023).

Molecular measurable residual disease methods

Molecular MRD methods.

Method Target Sensitivity Strengths and limits Source
Allele-specific oligonucleotide RT-qPCR of IG/TR rearrangements Patient-specific junctional region ≤10⁻⁴ Time-consuming and laborious; ASO primers can bind nonspecifically during B-cell regeneration van Dongen 2015
RT-qPCR of fusion transcripts or NPM1 mutations NPM1, RUNX1::RUNX1T1, CBFB::MYH11, PML::RARA 10⁻⁴ to 10⁻⁶ Oldest and most established molecular MRD method; preferred in AML when an assay exists Schuurhuis 2018; Duncavage 2022
Digital PCR Defined mutation or fusion Counts single molecules More accurate than qPCR for small numbers of target molecules Cross 2015
High-throughput sequencing of IG/TR Clonotypes identified at diagnosis Depends on DNA input; 10⁻⁶ not reached with 2–4 µg DNA No patient-specific primers; detects clonal evolution van Dongen 2015
Error-corrected NGS MRD panel Mutations from diagnosis About 0.1% VAF UMIs; follows each mutated clone, including persistent clonal hematopoiesis Duncavage 2022
  • Required sensitivity. MRD techniques in ALL aim for ≤10⁻⁴, and 10⁻⁴ to 10⁻⁵ to define risk groups accurately. Detection below 10⁻⁵–10⁻⁶ is limited by marrow cellularity (van Dongen 2015).
  • Replicates and positivity (ELN). qPCR MRD is run in triplicate, and positivity requires amplification in at least 2 of 3 replicates with Ct ≤40. Molecular progression in persistent low-level MRD is a rise of ≥1 log10 between any two positive samples (Schuurhuis 2018).
  • Positive not quantifiable. MRD detected outside the quantitative range of the standard curve is reported as positive not quantifiable (Della Starza 2023).
  • Cell input. An MRD assessment of 100 000 cells cannot reach a sensitivity of 10⁻⁶, even if the readout suggests that it did (Kim 2020).
  • Diagnostic sample. In AML, an RT-qPCR MRD target is measured in the diagnostic sample so that response kinetics can be estimated (Duncavage 2022).
  • Persistent clonal hematopoiesis. In remission, an NPM1-mutated founding clone can become undetectable by panel sequencing but remain detectable by MRD sequencing, while a DNMT3A clone with unchanged VAF indicates persistent clonal hematopoiesis (Duncavage 2022).
  • Flow cytometric MRD. EuroFlow approaches reach sensitivities below 10⁻⁴ to 10⁻⁵ and analyze ≥5 × 10⁶ cells (van Dongen 2015). Disease-specific MRD thresholds are taught in B- and T-Lymphoblastic Leukemia/Lymphoma: Genetic Subtypes, Immunophenotype and Measurable Residual Disease and Classification of Myeloid Neoplasms (WHO 5th Edition and ICC 2022), Flow Cytometry of Myeloid Neoplasms, Clonal Hematopoiesis, VEXAS Syndrome and Germline Predisposition.

Pharmacogenomic Genotyping, Identity and Parentage Testing with Short Tandem Repeats, Engraftment Monitoring and Molecular Infectious Disease Testing

Definition. These assays genotype polymorphic sites in the patient, donor or pathogen. Pharmacogenomic tests assign star-allele haplotypes and a predicted metabolizer phenotype (Pratt 2021). Short tandem repeat (STR) profiles identify individuals, establish parentage and measure donor chimerism after hematopoietic cell transplantation (Panneerchelvam 2023; Thelingwani 2024; Tozzo 2021). Quantitative nucleic acid tests measure viral load in international units, and genotypic tests detect antiviral resistance (Kotton 2025).

Related page: Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs (CPIC metabolizer terms and every gene–drug recommendation, AMP DPYD allele tiers) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (HLA typing, pharmacogenomic HLA alleles, chimerism interpretation and HLA-loss relapse) Related page: Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA (PCR, real-time PCR, digital PCR and capillary fragment analysis) Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (16S rRNA sequencing, NAAT, syndromic multiplex panels, metagenomic sequencing) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (MTB NAAT and resistance genotyping) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (resistance gene detection) Related page: Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile (C. difficile NAAT) Related page: Cervical Cancer Screening, Specimen Collection and Quality Assurance in Cervical Cytology (HPV testing in cervical screening)

Pharmacogenomic genotyping methods

  • Star-allele nomenclature. A star allele is a short-hand name for all variants on one haplotype. A person has two haplotypes, one on each chromosome, which form the diplotype; CYP2D6*2/*4 indicates one chromosome with the *2 haplotype and the other with *4 (Nofziger 2020).
  • Methods. Laboratories use targeted genotyping with laboratory-developed or commercial platforms, SNP arrays, or full-gene Sanger or NGS sequencing, with or without deletion, duplication and structural variant analysis. Genotype and copy-number results are combined to assemble haplotypes and diplotypes (Pratt 2021).
  • Default assignment. Many platforms test a limited number of variants. A variant shared by several alleles, such as c.100C>T (rs1065852) on CYP2D6*10, leads to a "default" call, and *1 is assigned when no variant is found. Default calls inflate the frequency of *1 and can misassign rare alleles (Nofziger 2020).
  • Allele tiers (AMP). Tier 1 alleles have a well-characterized functional effect, an appreciable minor allele frequency and publicly available reference materials. Tier 2 alleles meet at least one but not all of these criteria (Pratt 2021).

CYP2D6 structural variation.

Feature Description Source
Locus CYP2D6 is adjacent to the nonfunctional CYP2D7 and the CYP2D8 pseudogene; co-amplification of CYP2D7 causes erroneous calls Nofziger 2020
*5 Full gene deletion; no protein; allele frequency about 3%–5% in African, Asian and European populations Pratt 2021
Duplications and multiplications Written ×2, ×3 or ×N, without a standard notation; the functional effect depends on which allele is duplicated; long-range PCR identifies the duplicated allele Pratt 2021
Hybrid alleles CYP2D6–2D7 and CYP2D7–2D6 hybrids from gene conversion; *13 is a CYP2D7–CYP2D6 hybrid; hybrids occur alone or in tandem with other copies Pratt 2021; Nofziger 2020
*36 and *10 Both carry c.100C>T, a decreased-function variant Pratt 2021
Tier 1 alleles *2 to *6, *9, *10, *17, *29, *41 and the presence or absence of duplication or multiplication Pratt 2021
Tier 2 alleles *7, *8, *12, *14, *15, *21, *31, *40, *42, *49, *56, *59 and CYP2D6–2D7 hybrids Pratt 2021
Copy-number assays TaqMan, quantitative PCR and MLPA Pratt 2021

CYP2D6 activity score and phenotype, current and previous. Each allele receives an activity value: 0 for no function, 0.25 for CYP2D6*10, 0.5 for other decreased-function alleles and 1 for normal function. The value is multiplied by copy number and summed (Caudle 2020).

Phenotype CPIC–DPWG consensus 2020 (current) Previous CPIC definition Previous DPWG definition Source
Ultrarapid metabolizer >2.25 >2 >2.5 Caudle 2020
Normal metabolizer 1.25–2.25 1–2 1.5–2.5 Caudle 2020
Intermediate metabolizer >0 to <1.25 0.5 0.5–1 Caudle 2020
Poor metabolizer 0 0 0 Caudle 2020
  • Reason for the change. CPIC classified an activity score of 1.0 as normal metabolizer and DPWG classified it as intermediate. The consensus, accepted by 82% of 37 experts, downgraded CYP2D6*10 to 0.25 (Caudle 2020).
  • Reporting. The report gives the genotype (diplotype), the alleles tested and the predicted phenotype (Nofziger 2020; Pratt 2021).

Genotyping methods for other pharmacogenes. Dosing recommendations are taught in Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs.

Gene or allele Method facts Source
TPMT and NUDT15 Targeted genotyping or Sanger or NGS sequencing; AMP Tier 1 alleles are TPMT *2, *3A, *3B and *3C and NUDT15 *3 Pratt 2022
TPMT phasing Most genotyping and short-read NGS platforms cannot phase TPMT and NUDT15 variants; TPMT *41 can interfere with targeted testing for *3C Pratt 2022
TPMT and NUDT15 enzyme activity TPMT activity is a red cell assay and is not performed after recent transfusion or thiopurine treatment; no clinical NUDT15 activity assay exists Pratt 2022
DPYD Exome sequencing does not detect the intronic c.1129-5923C>G (HapB3); c.1236G>A has been used to infer it in Europeans Ho 2025
CYP2C19 The 2022 CPIC update revised genotype-to-phenotype translation Lee 2022
Panel coverage Panels may miss variants common in non-European populations, so a reference (*1/*1) call can be a false negative Siu 2025
HLA-B*57:01 Sensitivity >99% for flow cytometric pre-screening, real-time PCR and sequence-specific primer PCR with capillary electrophoresis; specificity 84.3%, 97.2% and >99% De Spiegelaere 2015

CPIC guidelines for these genes (Relling 2019; Amstutz 2018; Lee 2022; Martin 2012) and the AMP allele-selection recommendations for CYP2C19 (Pratt 2018) and DPYD (Pratt 2024) are applied in Therapeutic Drug Monitoring: Pharmacokinetics, Sampling and Assays for Antiepileptic, Antimicrobial, Immunosuppressant, Cardioactive, Psychiatric and Antineoplastic Drugs and HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.

Identity testing with short tandem repeats

  • Markers. STRs are repeats of 1–6 bp, also called microsatellites (Panneerchelvam 2023).
  • CODIS core loci, current and previous. In 2017 the FBI increased the core CODIS STR loci from 13 to 20: CSF1PO, FGA, TH01, TPOX, vWA, D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, D1S1656, D2S441, D2S1338, D10S1248, D12S391, D19S433 and D22S1045, with amelogenin for sex determination (Panneerchelvam 2023). The loci are used for their high heterozygosity, discriminatory power and simple amplification with commercial kits (Thelingwani 2024).
  • Capillary electrophoresis. Fluorescently labeled STR amplicons are separated by size in a fused-silica capillary about 50 µm wide filled with a sieving medium, and a laser detects them near the end of the capillary (Panneerchelvam 2023).
  • Degraded DNA. Forensic and post-mortem samples are often degraded and give less reliable profiles (Panneerchelvam 2023). For FFPE tissue, a degradation index above 1 indicates DNA fragmentation, and higher values indicate greater degradation (Lisman 2025).
  • MiniSTRs. MiniSTR primers bind sequences adjacent to the repeat to shorten the amplicon (Mautner 2017). The MiniFiler kit has a higher success rate with degraded or inhibited DNA and needs 0.125 ng of template compared with 0.5 ng for standard kits (van Oorschot 2010).
  • Low-template artifacts. Allele drop-out results from preferential amplification of one allele at a heterozygous locus, and allele drop-in from amplification artifacts such as stutter (van Oorschot 2010).
  • Mixture interpretation. Probabilistic genotyping software reports a likelihood ratio. Semi-continuous models weight drop-out and drop-in probabilities, and continuous models also use peak heights and model n − 1 stutter. Underestimating the number of contributors in low-level mixtures produced very low likelihood ratios (Gill 2021).
  • Chain of custody. Chain of custody documents the order in which evidence is handled. Evidence is packaged to prevent damage and sealed in tamper-evident bags or with tamper-evident tape (D'Anna 2023).

STR identity testing in surgical pathology.

Problem STR finding Example Source
Unsuspected specimen misidentification Discordant genotypes between two specimens from the same patient 1 of 972 specimen pairs ("molecular auditing") Demetrick 2018
Contaminating tissue fragment (floater) Profile of the microdissected fragment differs from the patient A low-grade B-cell lymphoma fragment among bone fragments was shown not to derive from the patient Mosse 2009
Absent tumor in a resection block Partial profiles from FFPE blocks matched the patient Partial profiles (8–9 of 15 loci) showed that the absent tumor resulted from an error at gross examination Raina 2011

Parentage and kinship testing

  • Paternity index. At each STR locus the paternity index (PI) is a likelihood ratio comparing the probability that the alleged father contributed the obligate paternal allele with the probability that a random man contributed it (Thelingwani 2024; Gjertson 2007).
  • Combined paternity index. The combined paternity index (CPI) is the product of the locus PIs (Thelingwani 2024).
  • Probability of paternity. The probability of paternity is CPI/(CPI + 1) (Thelingwani 2024).
  • Mutations. STR germline mutations, mostly single-step changes from strand slippage, cause isolated mismatches. Paternal and maternal mutation rates were 0.0021 and 0.0011 in one laboratory series. When a mismatch is attributed to mutation, the locus PI is calculated as μ/PE (mutation rate divided by the power of exclusion), as recommended by AABB (Thelingwani 2024).
  • Exclusion. In one series, true paternity exclusions showed 2–12 mismatched loci in duo cases and 4–18 in trio cases. That laboratory excluded paternity with four or more excluding loci and a CPI below 10 000 (Thelingwani 2024).
  • Exclusion rates. The overall paternity exclusion rate was 32.33% in 1135 cases. FGA, D2S1338, D18S51 and D2S441 were the most informative markers for exclusion (Thelingwani 2024).

Engraftment monitoring after hematopoietic cell transplantation

  • Principle. Chimerism testing identifies polymorphic DNA regions that differ between donor and recipient and measures the proportion of hematopoietic cells of each origin (Gravina 2026). STR-PCR is the most widely used method (Tozzo 2021; Gravina 2026).
  • Informative loci. Typical STR testing uses 14–16 loci, which almost always gives enough informative markers even with related donors (Gravina 2026). Markers are excluded from the calculation when a recipient stutter peak coincides with a donor peak or the reverse (Tozzo 2021).
  • Calculation. The percentage of recipient chimerism is the recipient peak area divided by the sum of recipient and donor peak areas at an informative locus (Tozzo 2021). Donor chimerism is 100% minus the recipient percentage.
  • Reference samples. Donor and recipient alleles are amplified in the same tube, so quantification does not require a pre-transplant sample for calibration. Recipient genotypes can be obtained after transplantation from hair follicles; buccal swabs after transplantation can show mixed chimerism (Tozzo 2021).
  • Categories. Complete chimerism is detection of the donor genotype only. Mixed chimerism is recipient DNA ≥1%, microchimerism is recipient DNA <1%, and split chimerism is recipient cells in one or more lineages (Tozzo 2021).
  • Lineage-specific testing. T cells are selected with CD3, myeloid cells with CD33, CD66b or CD15, and B cells with CD19 (Gravina 2026). Cell selection adds purification steps and cost (Tozzo 2021). Its value for predicting relapse is taught in HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.
  • Clinical meaning. Complete donor chimerism, typically >95%–99% donor cells, is associated with fewer relapses. Increasing mixed chimerism after complete chimerism correlates with relapse (Gravina 2026).

Chimerism methods and recipient DNA detection limits.

Method Marker Sensitivity for recipient DNA Informativity Source
STR-PCR with capillary electrophoresis STR, VNTR 1%–5% About 100% Gravina 2026
Quantitative PCR SNPs, indels 0.1%–1% 95%–100% Gravina 2026
XY FISH X and Y chromosomes <5% 100% in sex-mismatched transplants only Gravina 2026
NGS SNPs, indels 0.01%–0.1% About 100% Gravina 2026
  • qPCR limitations. Biallelic SNP and indel markers need large panels for informativity, may not discriminate in multi-donor transplants and require pre-transplant donor and recipient DNA for calibration (Tozzo 2021).

Viral load, resistance genotyping and syndromic panel testing

HIV-1, HBV and HCV quantitative assays.

Analyte Assay facts Source
Chemistry Aptima assays use target capture, transcription-mediated amplification and real-time detection; cobas assays use real-time PCR Park 2022
Calibration Assays are calibrated to WHO International Standards, for example the 2nd WHO International Standard for HIV-1 (NIBSC 97/650) Hatzakis 2016
HIV-1 RNA Quantifiable ranges 20–10 000 000 copies/mL (CAP/CTM v2.0) and 30–10 000 000 copies/mL (Aptima HIV-1 Quant Dx); lower limits of quantification 40 copies/mL (Abbott RealTime), 30 (Aptima) and 20 (cobas 6800) Hatzakis 2016; Wiesmann 2018
HBV DNA 10 to 1 × 10⁹ IU/mL on Aptima and cobas 6800; copies-to-IU conversion factors are assay-specific, for example 5.82 copies/IU (COBAS TaqMan) and 8.21 copies/IU (artus) Park 2022; Madihi 2020
HCV RNA 10 (Aptima) or 15 (cobas 6800) to 1 × 10⁸ IU/mL Park 2022
Allowable error A total allowable error of 0.5 log10 detects clinically significant differences in HIV and CMV viral load Newton 2022
HIV blips An isolated detectable viral load after suppression is generally attributed to random assay variation Wiesmann 2018
  • Quantitative assays. CMV quantitative nucleic acid tests (QNAT) calibrated to the WHO International Standard are used for diagnosis, surveillance for preemptive therapy and monitoring of treatment (Kotton 2025).
  • Units and reporting. Results are reported in IU/mL as log10 values, with integer values added if helpful (Kotton 2025).
  • Significant change. Only changes greater than 0.5 log10 IU/mL (3-fold) are considered significant, or greater than 0.7 log10 IU/mL (5-fold) when the initial value is below 3 log10 IU/mL (1000 IU/mL) (Kotton 2025).
  • Specimen type. Plasma or whole blood can be used, but results from the two specimen types are not comparable. One assay and one specimen type are used for each patient (Kotton 2025).
  • Quantification limits. Most CMV QNAT assays have a lower limit of quantification of 2–2.7 log10 IU/mL (100–500 IU/mL); newer automated platforms reach 1.5 log10 IU/mL (34.5 IU/mL) (Kotton 2025).
  • Thresholds. Universal treatment thresholds have not been established because published thresholds remain assay-specific. Transplant centers set their own (Kotton 2025).
  • Interlaboratory variability before standardization. In 33 laboratories testing a CMV panel in copies/mL, only 57.6% of results fell within ±0.5 log10 of the expected value, and laboratory-developed assays varied more than commercial reagents (Pang 2009). In 28 laboratories testing an EBV panel, 47.0% of results fell within ±0.5 log10. Viral load kinetics were judged more relevant than absolute values (Preiksaitis 2009).
  • Genotypic resistance testing. CMV genotyping includes UL97 (codons 335–665) and UL54 (codons 290–1000), mostly by Sanger sequencing. UL56 (codons 229–369) is sequenced for letermovir resistance. Usual UL97 ganciclovir-resistance mutations raise the EC50 5- to 15-fold (Kotton 2025).
  • Syndromic panel limits. A positive result may not distinguish colonization from active infection and may miss bacterial or fungal coinfection (Ramanan 2018). Conventional subculture and antimicrobial susceptibility testing are still required after blood culture panels (Ramanan 2018). Panel performance and 16S rRNA sequencing are taught in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
  • Fungal barcode. The nuclear ribosomal internal transcribed spacer (ITS) region is the primary fungal DNA barcode; the small subunit has poor species-level resolution in fungi (Schoch 2012).

References

  1. 42 CFR § 493.1253. Standard: Establishment and verification of performance specifications. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/cfr/text/42/493.1253 (accessed 2026-11-17)
  2. 42 CFR §§ 493.17, 493.25 and 493.1443. Test categorization; laboratories performing tests of high complexity; laboratory director qualifications for high-complexity testing. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/cfr/text/42/493.17 (accessed 2026-11-17)
  3. Abou Tayoun AN, Pesaran T, DiStefano MT, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat. 2018;39(11):1517-1524. doi:10.1002/humu.23626. PMID 30192042
  4. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2. PMID 35732829
  5. Alwine JC, Kemp DJ, Stark GR. Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl Acad Sci U S A. 1977;74(12):5350-5354. doi:10.1073/pnas.74.12.5350. PMID 414220
  6. Amare Amdiyee A, Sisay Tessema T. Isothermal nucleic acid amplification techniques: A comprehensive overview on their principle & applications as alternative to PCR. Pract Lab Med. 2026;49:e00523. doi:10.1016/j.plabm.2026.e00523. PMID 41816506
  7. American College of Medical Genetics and Genomics. ADDENDUM: Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2016;18(7):752. doi:10.1038/gim.2016.76. PMID 27359095
  8. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210–216. doi:10.1002/cpt.911. PMID 29152729
  9. Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59(3):253-268. doi:10.1007/s13353-018-0444-7. PMID 29680930
  10. Arghir A, Popescu R, Resmerita I, et al. Pallister-Killian Syndrome versus Trisomy 12p-A Clinical Study of 5 New Cases and a Literature Review. Genes (Basel). 2021;12(6):811. doi:10.3390/genes12060811. PMID 34073526
  11. Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223–1232. doi:10.1038/leu.2015.24. PMID 25650093
  12. Arreaza G, Qiu P, Pang L, et al. Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples. Int J Mol Sci. 2016;17(9):E1579. doi:10.3390/ijms17091579. PMID 27657050
  13. Aslanzadeh J. Preventing PCR amplification carryover contamination in a clinical laboratory. Ann Clin Lab Sci. 2004;34(4):389-396. PMID 15648778
  14. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547–560. doi:10.1007/s00401-012-1016-2. PMID 22810491
  15. Ball MK, Kollmeyer TM, Praska CE, et al. Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neurooncol Adv. 2020;2(1):vdaa109. doi:10.1093/noajnl/vdaa109. PMID 33205043
  16. Bartley AN, Mills AM, Konnick E, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022;146(10):1194–1210. doi:10.5858/arpa.2021-0632-cp. PMID 35920830
  17. Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016;146(6):647–669. doi:10.1093/ajcp/aqw206. PMID 28077399
  18. Bean L, Bayrak-Toydemir P, ACMG Laboratory Quality Assurance Committee. Addendum: American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet Med. 2021;23(12):2461. doi:10.1038/s41436-020-0893-3. PMID 32684629
  19. Beygo J, Buiting K, Ramsden SC, et al. Update of the EMQN/ACGS best practice guidelines for molecular analysis of Prader-Willi and Angelman syndromes. Eur J Hum Genet. 2019;27(9):1326–1340. doi:10.1038/s41431-019-0435-0. PMID 31235867
  20. Biancalana V, Glaeser D, McQuaid S, et al. EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders. Eur J Hum Genet. 2015;23(4):417–425. doi:10.1038/ejhg.2014.185. PMID 25227148
  21. Bill M, Jentzsch M, Bischof L, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2023;7(3):436–444. doi:10.1182/bloodadvances.2021005789. PMID 35381077
  22. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–5257. PMID 9823339
  23. Botkin JR, Belmont JW, Berg JS, et al. Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Hum Genet. 2015;97(1):6-21. doi:10.1016/j.ajhg.2015.05.022. PMID 26140447
  24. Bowen JM, Hernandez M, Johnson DS, et al. Diagnosis and management of vascular Ehlers-Danlos syndrome: Experience of the UK national diagnostic service, Sheffield. Eur J Hum Genet. 2023;31(7):749–760. doi:10.1038/s41431-023-01343-7. PMID 36977837
  25. Brandner S, McAleenan A, Jones HE, et al. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review. Neuropathol Appl Neurobiol. 2022;48(4):e12790. doi:10.1111/nan.12790. PMID 34958131
  26. Brandner S, McAleenan A, Kelly C, et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol. 2021;23(9):1457–1469. doi:10.1093/neuonc/noab105. PMID 34467991
  27. Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol. 2018;14(4):229–249. doi:10.1038/nrendo.2017.166. PMID 29377879
  28. Brnich SE, Abou Tayoun AN, Couch FJ, et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med. 2019;12(1):3. doi:10.1186/s13073-019-0690-2. PMID 31892348
  29. Camerota L, Ritelli M, Wischmeijer A, et al. Genotypic Categorization of Loeys-Dietz Syndrome Based on 24 Novel Families and Literature Data. Genes (Basel). 2019;10(10):E764. doi:10.3390/genes10100764. PMID 31569402
  30. Cancer Genome Atlas Research Network (TCGA), Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113. PMID 23636398
  31. Cancer Genome Atlas Research Network (TCGA). Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185–203.e13. doi:10.1016/j.ccell.2017.07.007. PMID 28810144
  32. Cancer Genome Atlas Research Network (TCGA). Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690. doi:10.1016/j.cell.2014.09.050. PMID 25417114
  33. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116–124. doi:10.1111/cts.12692. PMID 31647186
  34. Cazzato G, Caporusso C, Arezzo F, et al. Formalin-Fixed and Paraffin-Embedded Samples for Next Generation Sequencing: Problems and Solutions. Genes (Basel). 2021;12(10):1472. doi:10.3390/genes12101472. PMID 34680867
  35. Cereda A, Carey JC. The trisomy 18 syndrome. Orphanet J Rare Dis. 2012;7:81. doi:10.1186/1750-1172-7-81. PMID 23088440
  36. Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988;16(23):11141-11156. doi:10.1093/nar/16.23.11141. PMID 3205741
  37. Chavez-Ecos FA, Quispe-Vicuña C, Malaga M, et al. Accuracy of the molecular diagnosis of duchenne and becker muscular dystrophy: A systematic review with meta-analysis. PLoS One. 2026;21(7):e0345550. doi:10.1371/journal.pone.0345550. PMID 42479716
  38. Cheng L, Lopez-Beltran A, Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38. doi:10.1038/modpathol.2017.104. PMID 29148538
  39. Cheng S, Fockler C, Barnes WM, et al. Effective amplification of long targets from cloned inserts and human genomic DNA. Proc Natl Acad Sci U S A. 1994;91(12):5695-5699. doi:10.1073/pnas.91.12.5695. PMID 8202550
  40. Chiang J, Chua Z, Chan JY, et al. Strategies to improve implementation of cascade testing in hereditary cancer syndromes: a systematic review. NPJ Genom Med. 2024;9(1):26. doi:10.1038/s41525-024-00412-0. PMID 38570510
  41. Choi SE, Hong SW, Yoon SO. Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med. 2015;49(3):236-242. doi:10.4132/jptm.2015.03.16. PMID 26018515
  42. Chung Y, Nam SK, Chang HE, et al. Evaluation of an eight marker-panel including long mononucleotide repeat markers to detect microsatellite instability in colorectal, gastric, and endometrial cancers. BMC Cancer. 2023;23(1):1100. doi:10.1186/s12885-023-11607-6. PMID 37953261
  43. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3:16. doi:10.1038/s41525-018-0053-8. PMID 30002876
  44. Cloutier JM, Al-Rohil RN, Patel RM, et al. Ancillary Tools for the Diagnosis of CIC -Rearranged Sarcoma: A Comprehensive Review. J Cutan Pathol. 2025;52(4):324–331. doi:10.1111/cup.14792. PMID 39921488
  45. Cooley LD, Morton CC, Sanger WG, et al. Section E6.5-6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor-acquired chromosomal abnormalities. Genet Med. 2016;18(6):643-648. doi:10.1038/gim.2016.51. PMID 27124786
  46. Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999–1003. doi:10.1038/leu.2015.29. PMID 25652737
  47. Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150–2167. doi:10.1038/s41375-023-02048-y. PMID 37794101
  48. Cucchi DGJ, Vonk CM, Rijken M, et al. DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia. Blood Adv. 2021;5(21):4476–4479. doi:10.1182/bloodadvances.2021004980. PMID 34525176
  49. Cui C, Shu W, Li P. Fluorescence In situ Hybridization: Cell-Based Genetic Diagnostic and Research Applications. Front Cell Dev Biol. 2016;4:89. doi:10.3389/fcell.2016.00089. PMID 27656642
  50. Cusenza VY, Bisagni A, Rinaldini M, et al. Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches. Int J Mol Sci. 2021;22(9):4732. doi:10.3390/ijms22094732. PMID 33946969
  51. D'Anna T, Puntarello M, Cannella G, et al. The Chain of Custody in the Era of Modern Forensics: From the Classic Procedures for Gathering Evidence to the New Challenges Related to Digital Data. Healthcare (Basel). 2023;11(5):634. doi:10.3390/healthcare11050634. PMID 36900637
  52. De Spiegelaere W, Philippé J, Vervisch K, et al. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care. PLoS One. 2015;10(4):e0123525. doi:10.1371/journal.pone.0123525. PMID 25874872
  53. Deignan JL, Astbury C, Behlmann A, et al. Addendum: Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2021;23(12):2462. doi:10.1038/s41436-020-00961-6. PMID 33046848
  54. Deignan JL, Astbury C, Cutting GR, et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(8):1288–1295. doi:10.1038/s41436-020-0822-5. PMID 32404922
  55. Deignan JL, Gregg AR, Grody WW, et al. Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(8):100867. doi:10.1016/j.gim.2023.100867. PMID 37310422
  56. Della Starza I, De Novi LA, Elia L, et al. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers (Basel). 2023;15(2):374. doi:10.3390/cancers15020374. PMID 36672325
  57. Demetrick DJ. Molecular Auditing: An Evaluation of Unsuspected Tissue Specimen Misidentification. Arch Pathol Lab Med. 2018;142(11):1407–1414. doi:10.5858/arpa.2017-0374-oa. PMID 29911886
  58. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564-569. doi:10.1002/humu.22981. PMID 26931183
  59. Depienne C, Mandel JL. 30 years of repeat expansion disorders: What have we learned and what are the remaining challenges? Am J Hum Genet. 2021;108(5):764–785. doi:10.1016/j.ajhg.2021.03.011. PMID 33811808
  60. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990. doi:10.1038/nm.1789. PMID 18670422
  61. Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228–2247. doi:10.1182/blood.2022015853. PMID 36130297
  62. El-Gilany AH, Yahia S, Shoker M, et al. Cytogenetic and comorbidity profile of Down syndrome in Mansoura University Children's Hospital, Egypt. Indian J Hum Genet. 2011;17(3):157-163. doi:10.4103/0971-6866.92092. PMID 22345986
  63. Flucke U, van Noesel MM, Siozopoulou V, et al. EWSR1-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in Different Bone Lesions: An Updated Review. Diagnostics (Basel). 2021;11(6):1093. doi:10.3390/diagnostics11061093. PMID 34203801
  64. Garutti M, Foffano L, Mazzeo R, et al. Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool. Genes (Basel). 2023;14(5):1025. doi:10.3390/genes14051025. PMID 37239385
  65. Getman D, Lin M, Barakat N, et al. Analytical Performance Characteristics of a New Transcription-Mediated Amplification Assay for Treponema pallidum. J Clin Microbiol. 2021;59(8):e0051121. doi:10.1128/jcm.00511-21. PMID 33980645
  66. Gill P, Benschop C, Buckleton J, et al. A Review of Probabilistic Genotyping Systems: EuroForMix, DNAStatistX and STRmix™. Genes (Basel). 2021;12(10):1559. doi:10.3390/genes12101559. PMID 34680954
  67. Gjertson DW, Brenner CH, Baur MP, et al. ISFG: Recommendations on biostatistics in paternity testing. Forensic Sci Int Genet. 2007;1(3-4):223–231. doi:10.1016/j.fsigen.2007.06.006. PMID 19083766
  68. Gravholt CH, Andersen NH, Christin-Maitre S, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol. 2024;190(6):G53-G151. doi:10.1093/ejendo/lvae050. PMID 38748847
  69. Gravina M, Lepic K, Leber B, et al. Chimerism practices across Canadian transplant centres: review of current standards and variations. Front Transplant. 2026;5:1879340. doi:10.3389/frtra.2026.1879340. PMID 42602228
  70. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793-1806. doi:10.1038/s41436-021-01203-z. PMID 34285390
  71. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-483. doi:10.1038/gim.2013.47. PMID 23619275
  72. Hart RK, Fokkema IFAC, DiStefano M, et al. HGVS Nomenclature 2024: improvements to community engagement, usability, and computability. Genome Med. 2024;16(1):149. doi:10.1186/s13073-024-01421-5. PMID 39702242
  73. Hatanaka Y, Kuwata T, Morii E, et al. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. Pathol Int. 2021;71(11):725-740. doi:10.1111/pin.13170. PMID 34614280
  74. Hatzakis A, Papachristou H, Nair SJ, et al. Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0. Virol J. 2016;13(1):176. doi:10.1186/s12985-016-0627-y. PMID 27769309
  75. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710. doi:10.1126/science.1079666. PMID 12522257
  76. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821-9826. doi:10.1073/pnas.93.18.9821. PMID 8790415
  77. HGVS Nomenclature Committee. HGVS Nomenclature (21.1 series; 21.1.5): simple variant descriptions, reference sequences and protein frameshift recommendations. https://hgvs-nomenclature.org/stable/background/simple/, https://hgvs-nomenclature.org/stable/background/refseq/ and https://hgvs-nomenclature.org/stable/recommendations/protein/frameshift/ (accessed 2026-11-17)
  78. HGVS Nomenclature Committee. HGVS Nomenclature: simple variant descriptions and coding DNA numbering. https://hgvs-nomenclature.org/stable/background/simple/ (accessed 2026-11-17)
  79. Ho TT, Smith DM, Aquilante CL, et al. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clin Pharmacol Ther. 2025;117(5):1194–1208. doi:10.1002/cpt.3567. PMID 39887719
  80. Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24(5):986-998. doi:10.1016/j.gim.2022.01.001. PMID 35101336
  81. Howe B, Umrigar A, Tsien F. Chromosome preparation from cultured cells. J Vis Exp. 2014;(83):e50203. doi:10.3791/50203. PMID 24513647
  82. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37. doi:10.1182/blood-2006-01-0092. PMID 16522812
  83. Illumina. Quality Scores for Next-Generation Sequencing. Technical note. https://www.illumina.com/documents/products/technotes/technote_Q-Scores.pdf (accessed 2026-11-17)
  84. ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024). Cytogenet Genome Res. 2024;164(Suppl 1):1-224. doi:10.1159/000538512. PMID 39571546
  85. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-365. doi:10.1016/j.jmoldx.2017.01.011. PMID 28341590
  86. Joo JE, Mahmood K, Walker R, et al. Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers. Clin Epigenetics. 2023;15(1):95. doi:10.1186/s13148-023-01511-y. PMID 37270516
  87. Jørgensen JT. The current landscape of the FDA approved companion diagnostics. Transl Oncol. 2021;14(6):101063. doi:10.1016/j.tranon.2021.101063. PMID 33714919
  88. Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013;27(10):2032–2039. doi:10.1038/leu.2013.219. PMID 23860450
  89. Kafatos FC, Jones CW, Efstratiadis A. Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure. Nucleic Acids Res. 1979;7(6):1541-1552. doi:10.1093/nar/7.6.1541. PMID 503860
  90. Kalousek DK, Vekemans M. Confined placental mosaicism. J Med Genet. 1996;33(7):529-533. doi:10.1136/jmg.33.7.529. PMID 8818935
  91. Kaltenboeck B, Wang C. Advances in real-time PCR: application to clinical laboratory diagnostics. Adv Clin Chem. 2005;40:219-259. doi:10.1016/s0065-2423(05)40006-2. PMID 16355924
  92. Kamsteeg EJ, Kress W, Catalli C, et al. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet. 2012;20(12):1203–1208. doi:10.1038/ejhg.2012.108. PMID 22643181
  93. Kang BE, Zhang S, Lesmana H, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.∗97G>A), 2025 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2025;27(8):101466. doi:10.1016/j.gim.2025.101466. PMID 40616445
  94. Khider L, Gendron N, Mauge L. Inherited Thrombophilia in the Era of Direct Oral Anticoagulants. Int J Mol Sci. 2022;23(3):1821. doi:10.3390/ijms23031821. PMID 35163742
  95. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1. PMID 35732831
  96. Kim IS. Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation. Blood Res. 2020;55(S1):S19–S26. doi:10.5045/br.2020.s004. PMID 32719172
  97. Kim J, Kim HS, Nam M, et al. Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates. Cancer Metastasis Rev. 2025;44(3):58. doi:10.1007/s10555-025-10274-2. PMID 40576713
  98. Kim M, Joo JW, Lee SJ, et al. Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes. Cancers (Basel). 2020;12(3):E602. doi:10.3390/cancers12030602. PMID 32150988
  99. Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(23):9530-9535. doi:10.1073/pnas.1105422108. PMID 21586637
  100. Kingdom R, Wright CF. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. Front Genet. 2022;13:920390. doi:10.3389/fgene.2022.920390. PMID 35983412
  101. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823. doi:10.1073/pnas.68.4.820. PMID 5279523
  102. Kolgeci S, Kolgeci J, Azemi M, et al. Dermatoglyphics and Reproductive Risk in a Family with Robertsonian Translocation 14q;21q. Acta Inform Med. 2015;23(3):178-183. doi:10.5455/aim.2015.23.179-183. PMID 26236088
  103. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222–1245. doi:10.1200/jco.19.02960. PMID 31986064
  104. Kotton CN, Kumar D, Manuel O, et al. The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2025;109(7):1066–1110. doi:10.1097/tp.0000000000005374. PMID 40200403
  105. Kustanovich A, Schwartz R, Peretz T, et al. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20(8):1057-1067. doi:10.1080/15384047.2019.1598759. PMID 30990132
  106. Ladha FA, VanderPluym C, Mondragon-Estrada E, et al. Prothrombin G20210A and Factor V Leiden Variants Are Not Associated With Thrombotic Events in Congenital Heart Disease: An Observational Trial. J Am Heart Assoc. 2026;15(6):e046959. doi:10.1161/jaha.125.046959. PMID 41778605
  107. Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26(10):2159-2171. doi:10.1038/leu.2012.246. PMID 22918122
  108. Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526. PMID 35034351
  109. Lee K, Abul-Husn NS, Amendola LM, et al. ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2025;27(8):101454. doi:10.1016/j.gim.2025.101454. PMID 40568962
  110. Lenartz A, Scherer AM, Uhlmann WR, et al. The persistent lack of knowledge and misunderstanding of the Genetic Information Nondiscrimination Act (GINA) more than a decade after passage. Genet Med. 2021;23(12):2324-2334. doi:10.1038/s41436-021-01268-w. PMID 34400812
  111. Lesieur A, Thomas X, Nibourel O, et al. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica. 2021;106(6):1767–1769. doi:10.3324/haematol.2020.260133. PMID 33299234
  112. Levy B, Kanagal-Shamanna R, Sahajpal NS, et al. A framework for the clinical implementation of optical genome mapping in hematologic malignancies. Am J Hematol. 2024;99(4):642-661. doi:10.1002/ajh.27175. PMID 38164980
  113. Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. doi:10.1016/j.jmoldx.2016.10.002. PMID 27993330
  114. Liehr T, Weise A, Mrasek K, et al. Recombinant Chromosomes Resulting From Parental Pericentric Inversions-Two New Cases and a Review of the Literature. Front Genet. 2019;10:1165. doi:10.3389/fgene.2019.01165. PMID 31798640
  115. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129–159. doi:10.1016/j.jmoldx.2017.11.004. PMID 29398453
  116. Link-Lenczowska D, Pallisgaard N, Cordua S, et al. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. Ann Hematol. 2018;97(12):2299–2308. doi:10.1007/s00277-018-3451-1. PMID 30056580
  117. Lisman D, Ossowski A, Tołoczko-Grabarek A, et al. Forensic DNA Recovery from FFPE Tissue Using the Maxwell® RSC Xcelerate Kit: Optimization, Challenges, and Limitations. Genes (Basel). 2025;16(9):1074. doi:10.3390/genes16091074. PMID 41010019
  118. Liu Yin J, Cussen C, Harrington C, et al. Guideline Review: European Association for the Study of Liver (EASL) Clinical Practice Guidelines on Haemochromatosis. J Clin Exp Hepatol. 2023;13(4):649–655. doi:10.1016/j.jceh.2022.11.003. PMID 37440950
  119. Lo MC, Paterson A, Maraka J, et al. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. Br J Cancer. 2016;115(2):223–227. doi:10.1038/bjc.2016.106. PMID 27336602
  120. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–485. doi:10.1136/jmg.2009.072785. PMID 20591885
  121. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93(1):125-128. doi:10.1016/0378-1119(90)90145-h. PMID 2227421
  122. Losekoot M, van Belzen MJ, Seneca S, et al. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013;21(5):480–486. doi:10.1038/ejhg.2012.200. PMID 22990145
  123. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076
  124. Lucena-Aguilar G, Sánchez-López AM, Barberán-Aceituno C, et al. DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis. Biopreserv Biobank. 2016;14(4):264-270. doi:10.1089/bio.2015.0064. PMID 27158753
  125. Ma YL, Zhang WH, Chen GH, et al. Walking alone milestone combined reading-frame rule improves early prediction of Duchenne muscular dystrophy. Front Pediatr. 2022;10:985878. doi:10.3389/fped.2022.985878. PMID 36034570
  126. Madihi S, Syed H, Lazar F, et al. Performance Comparison of the artus HBV QS-RGQ and the CAP/CTM HBV v2.0 Assays regarding Hepatitis B Virus DNA Quantification. Biomed Res Int. 2020;2020:4159189. doi:10.1155/2020/4159189. PMID 32351992
  127. Maguire WF, Chang E, Mulkey F, et al. FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2026;32(20):4519–4524. doi:10.1158/1078-0432.ccr-26-1154. PMID 42584173
  128. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi:10.1002/ajmg.c.31552. PMID 28306229
  129. Mandelker D, Donoghue M, Talukdar S, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019;30(8):1221–1231. doi:10.1093/annonc/mdz136. PMID 31050713
  130. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(11):2029-2037. doi:10.1038/s41436-021-01242-6. PMID 34211152
  131. Mantere T, Kersten S, Hoischen A. Long-Read Sequencing Emerging in Medical Genetics. Front Genet. 2019;10:426. doi:10.3389/fgene.2019.00426. PMID 31134132
  132. Mantere T, Neveling K, Pebrel-Richard C, et al. Optical genome mapping enables constitutional chromosomal aberration detection. Am J Hum Genet. 2021;108(8):1409-1422. doi:10.1016/j.ajhg.2021.05.012. PMID 34237280
  133. Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–1427. doi:10.1093/annonc/mdz204. PMID 31268127
  134. Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021;27(17):4685–4689. doi:10.1158/1078-0432.ccr-21-0327. PMID 34083238
  135. Marcus L, Lemery SJ, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:10.1158/1078-0432.ccr-18-4070. PMID 30787022
  136. Marczyk VR, Fazeli S, Dadu R, et al. NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precis Oncol. 2025;9:e2400321. doi:10.1200/po.24.00321. PMID 39983078
  137. Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734–738. doi:10.1038/clpt.2011.355. PMID 22378157
  138. Massalska D, Ozdarska K, Roszkowski T, et al. Distribution of diandric and digynic triploidy depending on gestational age. J Assist Reprod Genet. 2021;38(9):2391-2395. doi:10.1007/s10815-021-02202-4. PMID 33982170
  139. Mautner ME, Pérez Santángelo A, Corti Bielsa RM, et al. Using long ssDNA polynucleotides to amplify STRs loci in degraded DNA samples. PLoS One. 2017;12(11):e0187190. doi:10.1371/journal.pone.0187190. PMID 29099837
  140. MedlinePlus Genetics. If a genetic disorder runs in my family, what are the chances that my children will have the condition? National Library of Medicine. https://medlineplus.gov/genetics/understanding/inheritance/riskassessment/ (accessed 2026-11-17)
  141. MedlinePlus Genetics. What are the different ways a genetic condition can be inherited? National Library of Medicine. https://medlineplus.gov/genetics/understanding/inheritance/inheritancepatterns/ (accessed 2026-11-17)
  142. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147. doi:10.1136/jitc-2019-000147. PMID 32217756
  143. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631-1641. doi:10.1200/jco.2017.76.8671. PMID 29504847
  144. Mikhail FM, Heerema NA, Rao KW, et al. Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities. Genet Med. 2016;18(6):635-642. doi:10.1038/gim.2016.50. PMID 27124785
  145. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764. doi:10.1016/j.ajhg.2010.04.006. PMID 20466091
  146. Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(8):100866. doi:10.1016/j.gim.2023.100866. PMID 37347242
  147. Milligan JN, Blasco-Pérez L, Costa-Roger M, et al. Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows. Genes (Basel). 2022;13(9):1657. doi:10.3390/genes13091657. PMID 36140824
  148. Moore S, McGowan-Jordan J, Smith AC, et al. Genome Mapping Nomenclature. Cytogenet Genome Res. 2023;163(5-6):236-246. doi:10.1159/000535684. PMID 38071973
  149. Morris JK, Alberman E. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ. 2009;339:b3794. doi:10.1136/bmj.b3794. PMID 19858532
  150. Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588–606. doi:10.1016/j.annonc.2024.04.005. PMID 38834388
  151. Mosse CA, Stumph JR, Best DH, et al. A B-cell lymphoma diagnosed in "floater" tissue: implications of the diagnosis and resolution of a laboratory error. Am J Med Sci. 2009;338(3):248–251. doi:10.1097/maj.0b013e3181a88dc0. PMID 19745614
  152. Mroczkowska-Bękarciak A, Wróbel T. BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing. Front Genet. 2023;14:1241912. doi:10.3389/fgene.2023.1241912. PMID 37745842
  153. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102. doi:10.1016/s1525-1578(10)60458-8. PMID 12707374
  154. Nagan N, Faulkner NE, Curtis C, et al. Laboratory guidelines for detection, interpretation, and reporting of maternal cell contamination in prenatal analyses a report of the association for molecular pathology. J Mol Diagn. 2011;13(1):7-11. doi:10.1016/j.jmoldx.2010.11.013. PMID 21227389
  155. Nevado J, Mergener R, Palomares-Bralo M, et al. New microdeletion and microduplication syndromes: A comprehensive review. Genet Mol Biol. 2014;37(1 Suppl):210-219. doi:10.1590/s1415-47572014000200007. PMID 24764755
  156. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516. doi:10.1093/nar/17.7.2503. PMID 2785681
  157. Newton DW, Vandepoele N, Yundt-Pacheco JC, et al. Management of Cytomegalovirus, Epstein-Barr Virus, and HIV Viral Load Quality Control Data Using Unity Real Time. J Clin Microbiol. 2022;60(1):e0167521. doi:10.1128/jcm.01675-21. PMID 34669458
  158. Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107(1):154–170. doi:10.1002/cpt.1643. PMID 31544239
  159. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33(14):e128. doi:10.1093/nar/gni127. PMID 16106041
  160. Ogino S, Wilson RB. Bayesian analysis and risk assessment in genetic counseling and testing. J Mol Diagn. 2004;6(1):1-9. doi:10.1016/s1525-1578(10)60484-9. PMID 14736820
  161. Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258–268. doi:10.1111/j.1600-6143.2008.02513.x. PMID 19178413
  162. Panneerchelvam S, Norazmi MN. DNA Profiling in Human Identification: From Past to Present. Malays J Med Sci. 2023;30(6):5–21. doi:10.21315/mjms2023.30.6.2. PMID 38239252
  163. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17(9):689–701. doi:10.1038/gim.2014.177. PMID 25503498
  164. Park Y, Roh J, Kim S. Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples. Ann Lab Med. 2022;42(4):447–456. doi:10.3343/alm.2022.42.4.447. PMID 35177565
  165. Pastore F, Greif PA, Schneider S, et al. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS One. 2014;9(10):e109759. doi:10.1371/journal.pone.0109759. PMID 25299584
  166. Pejaver V, Byrne AB, Feng BJ, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022;109(12):2163-2177. doi:10.1016/j.ajhg.2022.10.013. PMID 36413997
  167. Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019;364:k5222. doi:10.1136/bmj.k5222. PMID 30651232
  168. Poli F, Cattaneo R, Crespiatico L, et al. A rapid and simple method for reversing the inhibitory effect of heparin on PCR for HLA class II typing. PCR Methods Appl. 1993;2(4):356-358. doi:10.1101/gr.2.4.356. PMID 8324512
  169. Potter NT, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. Genet Med. 2004;6(1):61–65. doi:10.1097/01.gim.0000106165.74751.15. PMID 14726813
  170. Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn. 2021;23(9):1047–1064. doi:10.1016/j.jmoldx.2021.05.013. PMID 34118403
  171. Pratt VM, Cavallari LH, Fulmer ML, et al. DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn. 2024;26(10):851–863. doi:10.1016/j.jmoldx.2024.05.015. PMID 39032821
  172. Pratt VM, Cavallari LH, Fulmer ML, et al. TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2022;24(10):1051–1063. doi:10.1016/j.jmoldx.2022.06.007. PMID 35931343
  173. Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn. 2018;20(3):269–276. doi:10.1016/j.jmoldx.2018.01.011. PMID 29474986
  174. Preiksaitis JK, Pang XL, Fox JD, et al. Interlaboratory comparison of epstein-barr virus viral load assays. Am J Transplant. 2009;9(2):269–279. doi:10.1111/j.1600-6143.2008.02514.x. PMID 19178414
  175. Prins D, González Arias C, Klampfl T, et al. Mutant Calreticulin in the Myeloproliferative Neoplasms. Hemasphere. 2020;4(1):e333. doi:10.1097/hs9.0000000000000333. PMID 32382708
  176. Prior TW, Nagan N, Sugarman EA, et al. Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2011;13(7):686–694. doi:10.1097/gim.0b013e318220d523. PMID 21673580
  177. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443–453. doi:10.1056/nejmoa1603144. PMID 27433846
  178. Quan PL, Sauzade M, Brouzes E. dPCR: A Technology Review. Sensors (Basel). 2018;18(4):E1271. doi:10.3390/s18041271. PMID 29677144
  179. Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia. 2019;33(8):1851-1867. doi:10.1038/s41375-019-0378-z. PMID 30696948
  180. Raina A, Yadav B, Ali S, et al. Identification of tumor specimens by DNA analysis in a case of histocytological paraffin tissue block swapping. Croat Med J. 2011;52(3):410–414. doi:10.3325/cmj.2011.52.410. PMID 21674839
  181. Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic Panel-Based Testing in Clinical Microbiology. Clin Microbiol Rev. 2018;31(1):e00024–17. doi:10.1128/cmr.00024-17. PMID 29142077
  182. Rao X, Huang X, Zhou Z, et al. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71-85. PMID 25558171
  183. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928-1937. doi:10.1038/s41591-019-0652-7. PMID 31768066
  184. Reddy UM, Page GP, Saade GR, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med. 2012;367(23):2185-2193. doi:10.1056/nejmoa1201569. PMID 23215556
  185. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095–1105. doi:10.1002/cpt.1304. PMID 30447069
  186. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30. PMID 25741868
  187. Ridder LO, Berglund A, Stochholm K, et al. Morbidity, mortality, and socioeconomics in Klinefelter syndrome and 47,XYY syndrome: a comparative review. Endocr Connect. 2023;12(5):e230024. doi:10.1530/ec-23-0024. PMID 37098811
  188. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22(2):245-257. doi:10.1038/s41436-019-0686-8. PMID 31690835
  189. Roy S, Coldren C, Karunamurthy A, et al. Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn. 2018;20(1):4-27. doi:10.1016/j.jmoldx.2017.11.003. PMID 29154853
  190. Santoli CMA, Dotters-Katz SK, Sparks TN, et al. An overview of current prenatal genetic screening and diagnosis guidelines. Pregnancy (Hoboken). 2025;1(3):e70016. doi:10.1002/pmf2.70016. PMID 42597132
  191. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70-84. doi:10.32074/1591-951x-213. PMID 33179614
  192. Scheerens H, Malong A, Bassett K, et al. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. Clin Transl Sci. 2017;10(2):84-92. doi:10.1111/cts.12455. PMID 28121072
  193. Schoch CL, Seifert KA, Huhndorf S, et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci U S A. 2012;109(16):6241–6246. doi:10.1073/pnas.1117018109. PMID 22454494
  194. Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet. 2012;13(12):878–890. doi:10.1038/nrg3275. PMID 23154810
  195. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57. doi:10.1093/nar/gnf056. PMID 12060695
  196. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3. doi:10.1186/1471-2199-7-3. PMID 16448564
  197. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291. doi:10.1182/blood-2017-09-801498. PMID 29330221
  198. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017;19(2):187–225. doi:10.1016/j.jmoldx.2016.11.001. PMID 28185757
  199. Seto A, Downs G, King O, et al. Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia. Cancers (Basel). 2024;16(9):1693. doi:10.3390/cancers16091693. PMID 38730645
  200. Silva M, de Leeuw N, Mann K, et al. European guidelines for constitutional cytogenomic analysis. Eur J Hum Genet. 2019;27(1):1-16. doi:10.1038/s41431-018-0244-x. PMID 30275486
  201. Siu WS, Maruf AA, Shaheen SM, et al. Estimating the Frequency of False-Negative Pharmacogenetic Test Results by Self-Reported Ancestry. Clin Pharmacol Ther. 2025;118(2):331–336. doi:10.1002/cpt.3697. PMID 40287944
  202. Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46. doi:10.1038/s41379-019-0324-7. PMID 31375766
  203. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975;98(3):503-517. doi:10.1016/s0022-2836(75)80083-0. PMID 1195397
  204. Spector E, Behlmann A, Kronquist K, et al. Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(5):799–812. doi:10.1038/s41436-021-01115-y. PMID 33795824
  205. Stenton SL, Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784. doi:10.1016/j.ebiom.2020.102784. PMID 32454403
  206. Stenzinger A, Allen JD, Maas J, et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019;58(8):578–588. doi:10.1002/gcc.22733. PMID 30664300
  207. Stuppia L, Antonucci I, Palka G, et al. Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci. 2012;13(3):3245-3276. doi:10.3390/ijms13033245. PMID 22489151
  208. Sun Y, Chen J, Li J, et al. Novel approach based on one-tube nested PCR and a lateral flow strip for highly sensitive diagnosis of tuberculous meningitis. PLoS One. 2017;12(10):e0186985. doi:10.1371/journal.pone.0186985. PMID 29084241
  209. Sura GH, Engel KB, Greytak SR, et al. Pre-analytical Best Practices for RNA Sequencing from Small Biopsies and Cytologic Specimens. Mol Diagn Ther. 2026;30(3):441-461. doi:10.1007/s40291-026-00837-6. PMID 41831145
  210. Svec D, Tichopad A, Novosadova V, et al. How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments. Biomol Detect Quantif. 2015;3:9-16. doi:10.1016/j.bdq.2015.01.005. PMID 27077029
  211. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 263. doi:10.1038/ajg.2014.435. PMID 25645574
  212. Tartaglia NR, Howell S, Sutherland A, et al. A review of trisomy X (47,XXX). Orphanet J Rare Dis. 2010;5:8. doi:10.1186/1750-1172-5-8. PMID 20459843
  213. Tavtigian SV, Greenblatt MS, Harrison SM, et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20(9):1054-1060. doi:10.1038/gim.2017.210. PMID 29300386
  214. Tavtigian SV, Harrison SM, Boucher KM, et al. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat. 2020;41(10):1734-1737. doi:10.1002/humu.24088. PMID 32720330
  215. Taylor AC. Titration of heparinase for removal of the PCR-inhibitory effect of heparin in DNA samples. Mol Ecol. 1997;6(4):383-385. doi:10.1046/j.1365-294x.1997.00191.x. PMID 9131813
  216. Thelingwani RS, Jonhera CA, Masimirembwa C. Analysis of data and common mutations encountered during routine parentage testing in Zimbabwe. Sci Rep. 2024;14(1):1385. doi:10.1038/s41598-024-51987-8. PMID 38228706
  217. Tozzo P, Delicati A, Zambello R, et al. Chimerism Monitoring Techniques after Hematopoietic Stem Cell Transplantation: An Overview of the Last 15 Years of Innovations. Diagnostics (Basel). 2021;11(4):621. doi:10.3390/diagnostics11040621. PMID 33808342
  218. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425-432. doi:10.2353/jmoldx.2010.090188. PMID 20431034
  219. van den Brand M, Möbs M, Otto F, et al. EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing: A Structured Approach with the DEPART Algorithm. J Mol Diagn. 2023;25(10):729–739. doi:10.1016/j.jmoldx.2023.06.011. PMID 37467928
  220. van den Brand M, Rijntjes J, Möbs M, et al. Next-Generation Sequencing-Based Clonality Assessment of Ig Gene Rearrangements: A Multicenter Validation Study by EuroClonality-NGS. J Mol Diagn. 2021;23(9):1105–1115. doi:10.1016/j.jmoldx.2021.06.005. PMID 34186174
  221. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–2317. doi:10.1038/sj.leu.2403202. PMID 14671650
  222. van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009. doi:10.1182/blood-2015-03-580027. PMID 25999452
  223. van Oorschot RA, Ballantyne KN, Mitchell RJ. Forensic trace DNA: a review. Investig Genet. 2010;1(1):14. doi:10.1186/2041-2223-1-14. PMID 21122102
  224. Vikas P, Messersmith H, Compton C, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023;41(10):1943–1948. doi:10.1200/jco.22.02462. PMID 36603179
  225. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.1235122. PMID 23539594
  226. Wakeling E, Davies JH, Giabicani E, et al. Diagnosis and management of Silver-Russell syndrome: second international consensus statement. Nat Rev Endocrinol. 2026. doi:10.1038/s41574-026-01303-3. PMID 42778655
  227. Wang H, Lai Y, Wen J, et al. [Key updates in the 2024 Edition of the International System for Human Cytogenomic Nomenclature (ISCN)]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2025;42(7):848-854. doi:10.3760/cma.j.cn511374-20250523-00324. PMID 40947411
  228. Watzinger F, Ebner K, Lion T. Detection and monitoring of virus infections by real-time PCR. Mol Aspects Med. 2006;27(2-3):254-298. doi:10.1016/j.mam.2005.12.001. PMID 16481036
  229. Weise A, Mrasek K, Klein E, et al. Microdeletion and microduplication syndromes. J Histochem Cytochem. 2012;60(5):346-358. doi:10.1369/0022155412440001. PMID 22396478
  230. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186. doi:10.1038/s41571-020-00447-z. PMID 33293629
  231. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335. PMID 25810047
  232. Wesseling P, Capper D, Reifenberger G, et al. cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors. Brain Pathol. 2026;36(1):e70035. doi:10.1111/bpa.70035. PMID 40887057
  233. Wiesmann F, Ehret R, Naeth G, et al. Multicenter Evaluation of Two Next-Generation HIV-1 Quantitation Assays, Aptima Quant Dx and Cobas 6800, in Comparison to the RealTime HIV-1 Reference Assay. J Clin Microbiol. 2018;56(10):e00292–18. doi:10.1128/jcm.00292-18. PMID 30068537
  234. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307–1367. doi:10.1093/europace/euac030. PMID 35373836
  235. Wisconsin State Laboratory of Hygiene, Clinical Cytogenetics. Basic nomenclature for cytogenetics (based on ISCN 2013). https://www.slh.wisc.edu/clinical/cytogenetics/education/basics (accessed 2026-11-17)
  236. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867–3872. doi:10.1200/jco.22.02864. PMID 37284804
  237. Wolff DJ, Bagg A, Cooley LD, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007;9(2):134-143. doi:10.2353/jmoldx.2007.060128. PMID 17384204
  238. Xiao B, Liu H, Sun Y, et al. Beyond carrier frequency: a preliminary multicenter study of simultaneous couple-based comprehensive carrier screening for common and rare genetic disorders. Genome Med. 2026;18(1):85. doi:10.1186/s13073-026-01628-8. PMID 42026640
  239. Yanagita E, Yamada H, Kobayashi T, et al. The DNA integrity number and concentration are useful parameters for successful comprehensive genomic profiling test for cancer using formalin-fixed paraffin embedded tissue. Pathol Int. 2023;73(5):198-206. doi:10.1111/pin.13318. PMID 36971494
  240. Zaidi AA, Wilton PR, Su MS, et al. Bottleneck and selection in the germline and maternal age influence transmission of mitochondrial DNA in human pedigrees. Proc Natl Acad Sci U S A. 2019;116(50):25172–25178. doi:10.1073/pnas.1906331116. PMID 31757848
  241. Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(12):1489–1498. doi:10.1038/s41436-018-0322-z. PMID 30297698
  242. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479-1484. doi:10.1038/nm.3729. PMID 25384085